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Adipose triglyceride lipase (ATGL) catalyzes the degradation of cellular triacylglycerol stores and strongly
determines the concentration of circulating fatty acids (FAs). High serum FA levels are causally linked to
the development of insulin resistance and impaired glucose tolerance, which eventually progresses to
overt type 2 diabetes. ATGL-speciﬁc inhibitors could be used to lower circulating FAs, which can counter-
act the development of insulin resistance. In this article, we report about structure–activity relationship
(SAR) studies of small molecule inhibitors of ATGL based on a hydrazone chemotype. The SAR indicated
that the binding pocket of ATGL requests rather linear compounds without bulky substituents. The best
inhibitor showed an IC50 = 10 lM in an assay with COS7-cell lysate overexpressing murine ATGL.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
During the last decades increasing evidence has emerged that
fatty acid (FA) metabolism is closely linked to the development
of metabolic disorders. Increased circulating FAs, as observed in
obesity, can cause FA overload of non-adipose tissues resulting in
ectopic triglyceride (TG) accumulation which is associated with
impaired metabolic functions of these tissues, insulin resistance,
and inﬂammation.1 Thus, decreasing plasma FA levels represents
an apparent strategy to counteract the development of metabolic
disease.
Plasma FA levels are strongly determined by lipases catalyzing
the degradation of TG stores in adipose tissue. Efﬁcient FA
mobilization requires the activity of two lipases: Adipose triglyc-
eride lipase (ATGL) and hormone-sensitive lipase (HSL). ATGL
releases the ﬁrst FA from the TG molecule and generates diacyl-
glycerol (DG).2 Hormone-sensitive lipase (HSL) is the rate-limiting
enzyme for the hydrolysis of DG,3 but is also capable of hydrolyz-
ing TG and monoglycerides.4,5 Since ATGL performs the ﬁrst and
rate-limiting step in lipolysis, inhibition of this enzyme is a
powerful way to reduce FA availability. Accordingly, publisheddata demonstrate that ATGL-deﬁcient mice exhibit low plasma
FA levels, improved glucose tolerance and insulin sensitivity, and
are resistant to high-fat diet-induced insulin resistance.6–9
Furthermore, pharmacological inhibition of ATGL reduces circulat-
ing FAs and triglyceride levels.10
It is important to note that defective ATGL function is associated
with systemic TG accumulation in humans and rodents.6 Humans
with defective ATGL function develop cardiomyopathy at the age
of 30 years due to massive accumulation of TG in cardiomy-
ocytes.11 Thus, it is reasonable to assume that also inhibitor-medi-
ated ablation of ATGL activity can cause cardiac TG accumulation
and myopathy. However, transient or partial inhibition of ATGL
must not necessarily result in cardiac TG accumulation, since tis-
sue TG stores can be rapidly mobilized to generate FA for energy
conversion or as building blocks for complex lipids. Furthermore,
small molecule inhibitors often show speciﬁc tissue distribution
patterns which avoid their accumulation in cardiomyocytes, as
recently demonstrated for the ATGL inhibitor Atglistatin.10
The signiﬁcant biological relevance of ATGL makes it desirable
to identify inhibitors of ATGL as tool compounds to study its bio-
logical role and validate ATGL as a potential drug target.
However, at present no 3D-structure of ATGL is available and any
effort to identify inhibitors of ATGL has to rely on the traditional
approach of synthesizing and testing compounds. Recently, we
have described a ﬁrst inhibitor of murine ATGL, Atglistatin (B),10
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from a high-throughput screening (HTS) campaign originally
aimed to inhibit HSL. In parallel to that work we have also followed
a second hit compound 1a based on a hydrazone chemotype,
which had slightly better initial activity against ATGL
(IC50 = 110 lM). Here we report about our efforts to develop 1a
as a tool compound and discuss the structure–activity data gained
from this hydrazone chemotype (Fig. 1).
2. Results and discussion
2.1. Chemistry
Lead structure 1a resulting from the HTS can be characterized
by a hydrophobic side chain represented by the phenylpiperazine
moiety connected with a catechol moiety via a hydrazone linkage.
While we were aware about the problem associated with the
intrinsic toxicity associated with hydrazones, we found the ready
accessibility and synthetic ﬂexibility of hydrazones attractive to
gain fast insight into the structure–activity relationship of this
inhibitor chemotype and hoped to be able to replace the hydrazone
later by a more innocent functional group.12
In the ﬁrst stage of our optimization studies we synthesized a
set of compounds 1b–1z, in which we varied the catechol sub-
stituent of hit compound 1a by differently substituted aryl and ali-
phatic aldehydes in the hydrazone forming process (Scheme 1).
Starting from commercial N-phenylpiperazine nitrosation with
tert-butylnitrite13 followed by reduction with LiAlH414 delivered
the desired 4-phenylpiperazin-1-amine in 74% yield. This central
nucleophile was then reacted with 26 differently substitutedNNN
HO
HO
N
N
O
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N
N
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Figure 1. Hit compounds which served for the development of tool compounds
against ATGL.
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Scheme 1. Synthesis of test compounds via hydrazonbenzaldehydes in toluene at 100 C producing the hydrazones
1a–1z in 44–99% yield (Table 1).15 Similarly, another set of ten ali-
phatic and aromatic aldehydes was reacted with the same hydra-
zine under similar conditions to produce the hydrazones 2a–2j in
82–99% yield (Scheme 2, Table 2).
In the second stage of our studies we put our focus on the
piperazine function by exchanging on the one hand the N-phenyl
substituent at the piperazine by other N-aryl and N-alkyl sub-
stituents (compounds 3a–3g, Table 3) and on the other hand by
replacing the piperazine with a piperidine or homopiperazine ring
(compounds 3h–3j, Table 3). The proven substitution pattern from
the hit compound representing the 2,4-dihydroxyphenylic system
was kept constant in the aldehyde reactant in these studies
(Scheme 3).
The synthesis of the homopiperazine compound 3j started with
a Pd(0)-catalyzed Buchwald–Hartwig-arylation of Boc-protected
homopiperazine (4) with bromobenzene using Pd(OAc)2/X-Phos
with NaOtBu as base,16 which after deprotection with HCl deliv-
ered the homopiperazine as its hydrochloride salt 5 in moderate
29% yield (Scheme 4). Nitrosylation of 5 and reduction with
LiAlH414 produced hydrazine 6 in 24% yield, which could then
smoothly react with 2,4-dihydroxybenzaldehyde to the desired
condensation product 3j in 97% yield.
In the ﬁnal stage of our structure activity studies we attempted
to replace the hydrazone linkage with other linking units
(Scheme 5). The more stable, but by one atom shorter, test com-
pound 8was prepared by reductive amination of 3,4-dihydroxyben-
zaldehyde (7) and N-phenylpiperidine with NaBH(OAc)3.17 For
reasons of synthetic accessibility the 2,4-dihydroxyphenylic system
was replaced in the synthesis of the following test compounds by
other successful aldehyde fragments from the ﬁrst stage of
optimization, which did not have the reactive phenolic OH
groups and were replaced by MeO and F substituents, which
would also be less prone to phase 2 metabolism.12 The hydrazide
analog 10 was synthesized via reaction of the acid chloride
prepared from 9 with 4-phenylpiperazin-1-amine in 53%
overall yield. For the synthesis of urea analog 12, aniline 11 was
ﬁrst converted into the Boc-carbamate, which was then reacted
with N-lithiated phenylpiperazine delivering 12 in 25% overall
yield.18 Finally, urethane 14was prepared by following a strategy,19
in which phenol 13 is ﬁrst activated with 1,10-carbonyldiimidazole
(CDI) to an aryloxycarbonylimidazol and then reacted with
1-phenylpiperazine to produce the desired carbamate in 20% overall
yield.
2.2. Biological activity
All synthesized test compounds were screened for their efﬁ-
ciency to inhibit ATGL activity in vitro in an assay using radiola-
belled triolein as substrate.20 As ATGL cannot be puriﬁed, the
assays were performed with COS7-cell lysates from cellsN
NNN
H
O
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e formation with aliphatic and arylic aldehydes.
Table 1
Screening data of hydrazones 1a–z produced via Scheme 1
Entry Compound R1 R2 R3 R4 Yield (%) IC50 (%) I200 (%)
1 1a –H –OH –OH –H 92 110 69
2 1b –H –OMe –OMe –H 99 100 65
3 1c –H –OH –OMe –H 99 80 56
4 1d –H –OMe –OH –H 68 60 82
5 1e –H –OH –H –H 50 70 71
6 1f –OH –H –H –H 99 75 64
7 1g –H –OH –H –H 99 50 85
8 1h –OH –H –OH –H 99 10 94
9 1i –H –OnPr –H –H 71 >200 14
10 1j –H –OPh –H –H 94 >200 24
11 1k –OMe –H –OMe –OMe 83 >200 43
12 1l –H –OMe –OMe –OMe 44 >200 41
13 1m –H –F –F –H 90 75 67
14 1n –H –Cl –Cl –H 90 >200 20
15 1o –Cl –H –Cl –H 95 >200 42
16 1p –NO2 –H –H –H 97 180 60
17 1q –Br –H –H –H 89 >150 73
18 1r –CN –H –H –H 99 120 60
19 1s –H –H –CN –H 92 50 76
20 1t –H –H –CH3 –H 99 >200 22
21 1u –H –H –NMe2 –H 61 >200 5
22 1v –H –H –NHAc –H 96 >200 14
23 1w –H –H –N(Me)(CH2)2OH –H 84 >200 5
24 1x –H –OCH2O– –OCH2O– –H 87 >200 64
25 1y –H –O(CH2)2O– –O(CH2)2O– –H 95 >200 27
26 1z –H –NHCONH– –NHCONH– –H 99 >200 16
NNH2N NNN
R
R H
O toluene, 100 °C
2a-j
+
Scheme 2. Synthesis of test compounds via hydrazone formation with aliphatic
and arylic aldehydes.
Table 2
Screening data of hydrazones 2a–j produced via Scheme 2
Entry Compound R Yield (%) IC50 (%) I200 (%)
1 2a 94 >200 12
2 2b 99 >200 12
3 2c 98 200 49
4 2d 94 130 58
5 2e
N
87 >200 16
6 2f
N
99 >200 46
7 2g N 99 140 60
8 2h 82 >200 <1
9 2i
N
83 >200 8
10 2j 98 200 49
Table 3
Screening data of hydrazones 3a–j produced via Scheme 3
Entry Compound R Yield (%) IC50 (%) I200 (%)
1 3a N N N 74 >200 19
2 3b N N F 25 50 78
3 3c N N 58 >200 44
4 3d
N N
95 >200 48
5 3e N N 95 >200 14
6 3f N N 66 >200 25
7 3g N N 76 >200 36
8 3h N 57 40 81
9 3i
N
95 >200 26
10 3j
N
N 97 >200 87
2906 N. Mayer et al. / Bioorg. Med. Chem. 23 (2015) 2904–2916overexpressing recombinant murine ATGL. For the determination
of the IC50-value inhibitors were administered with increasing con-
centrations to the enzyme and its substrate. To determine the
ATGL-inhibition efﬁciency at 200 lM (I200), 200 lM inhibitor was
administered to the enzyme and its substrate. The results of the
ﬁrst set of test compounds 1a–1z are summarized in Table 1. TheIC50-values and the inhibition of the enzyme using an inhibitor
concentration of 200 lM are listed. Starting from the hit compound
1a from the HTS (entry 1) the inﬂuence of the HO substituents on
the biological activity was investigated. As catechols are known to
be oxidation sensitive and to be metabolized very fast in organ-
isms, we varied the amount and position of HO substituents (1e–
1h) and partly replaced them by methoxy groups (1b–1d). The
activity increased in comparison to 1a if one of the HO groups
was methylated (entries 3 and 4). Even more pronounced was
the activity gain if only a single HO substituent was present at
RH2N RN
H
O toluene, 100 °C
3a-j
+
OH
OH
HO
HO
Scheme 3. Synthetic access to second set of test compounds by variation of the
piperazine moiety.
N. Mayer et al. / Bioorg. Med. Chem. 23 (2015) 2904–2916 2907the aldehyde building block (entries 5–7). The highest activity was
observed for compound 1h with its 2,4-dihydroxyphenyl moiety
(IC50 = 10 lM, entry 8). If the HO substituents in the hit compound
1awere substituted by ﬂuorines the activity was slightly improved
(IC50 = 75 lM, 1m, entry 13), whereas the corresponding Cl-analog
1n was inactive (entry 14) as also its structural isomer (entry 15).
The comparison of ortho-hydroxylated compound 1f with the
analogous substrates 1p–1r showed that –NO2, –Br or –CN sub-
stitution led to less active compounds (entries 16–18). From the
data of the ﬁrst screening it also became apparent, that bulky3j
N NBoc H HN N
N NN
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Scheme 5. Synthesis of test compounsubstituents or multiple substitution leading to sterically demand-
ing compounds resulted in inactive compounds (entries 9–12 and
20–26). Interestingly, the rather linear 4-cyanosubstituted com-
pound 1s (IC50 = 50 lM, entry 19) had encouraging activity, while
the bulkier 4-methylsubstituted analog 1t (entry 20) was inactive,
providing further evidence for a rather small and linear binding
pocket of ATGL.
In the second set of screening compounds, the phenyl group of
the aldehyde was replaced by alkyl, aryl and hetaryl groups
(Table 2). From this set of compounds only the 1-cyclohexen-1-yl
compound 2d (entry 4) and 4-pyridyl compound 2g (entry 7)
showed moderate activity, while all other compounds were more
or less inactive, corroborating the results from Table 1 that struc-
tures bulkier than the phenyl ring in hit compound 1a seem to
ﬁt less well into the binding pocket.
In the next stage of our optimization studies we kept the best
scoring fragment 2,4-dihydroxyphenyl (identiﬁed above from the
screening of compounds in Tables 1 and 2) and varied the N-N NH2N
N NH2N
O
OH
2.2 eq LiAlH4
THF, reflux 24 %
3.1 eq tBuONO
5 eq Et3N
THF, relux, o.n.
quant.
100 °C, o.n.
97 %
6
mopiperazine compound 3j.
N
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N
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rnight
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O
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N N
5 h
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10
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N N
12
O
ux 5 h
O
F
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N N
14
O
ds with hydrazone bioisosteres.
Table 4
Screening data of alternative test compounds produced via Scheme 5
Entry Compound IC50 (%) I200 (%)
1 8 >200 20
2 10 >200 38
3 12 >200 40
4 14 110 57
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gest that any variation which leads to increased steric bulk by
offering additional substituents or non-sp2-elements (entries 3–7,
9 and 10) were more or less inactive. Only the rather slim 4-ﬂuo-
rophenylpiperazine substrate 3b (IC50 = 50 lM, entry 2) and the
phenylpiperidino compound 3h (IC50 = 40 lM, entry 8) resulted
in active compounds, although the biological activity was lower
in comparison to parent structure 1h. The data direct to the follow-
ing insights regarding the SAR: the space in the binding pocket
seems to be limited as by introduction of nonplanarity in the case
of cyclohexyl and cyclopentyl ring systems the activity gets lost
and the hydrophobic p–p-interaction of an aromatic ring seems
to be favorable.
As the hydrazone moiety is regarded as a problematic molecular
group due to its metabolic instability resulting in toxic side prod-
ucts,12 we prepared compound 8 which can be regarded as a vari-
ant of 1a missing one nitrogen atom (Scheme 5). However, this
compound turned out to be biologically inactive (entry 1,
Table 4). Although hydrazide 10 is a structurally very close analog
to the active hydrazone 1b (Table 1) the hydrazone/hydrazide
switch resulted in an inactive compound (entry 2, Table 4). An
inverso switch of the amido group of 10 led to urea compound
12, which again showed no biological activity against ATGL (entry
3, Table 4). However, when introducing the carbamate moiety
group in 14, which is a structural analog of 1m (entry 13,
Table 1) an active but less potent compound (IC50 = 110 lM, entry
4, Table 4) could be generated, which might give rise to a covalent
binding inhibitor based on the intrinsic reactivity of phenol-
carbamates. Taken together these efforts have shown that the
hydrazone moiety is an essential element of the biological activity
of the hit compound 1a and could not be replaced by the most
obvious structural isosteres. In order to further characterize our
hit compound 1a and best inhibitor 1h, these compounds were
tested for ATGL- and HSL-selectivity by the determination of
lipolysis in WAT (white adipose tissue) organ cultures of wild-type,
ATGL-ko, and HSL-ko mice. Although the assay revealed a dose
dependent reduction of FA release, lipolysis was similarly
decreased in ATGL and HSL deﬁcient adipose tissue indicating that
the compounds 1a and 1h show no selectivity between ATGL and
HSL (Suppl. Fig. 1).
Further studies revealed that compound 1h does not inhibit
monoglyceride lipase (MGL), or lipoprotein lipase (Suppl. Fig. 2),
but was determined to be toxic (Tox 4 toxicity test, Suppl. Fig. 3)
suggesting that the hydrazone moiety contributes to this outcome.
3. Conclusion
In summary, we could show that hydrazones resulting from the
condensation of electron rich benzaldehydes with 4-phenylpipera-
zin-1-amine result in quite active inhibitors of ATGL. The best com-
pound 1h exhibits respectable biological activity (IC50 = 10 lM)
considering that the ATGL assay is performed with cell lysate
instead of puriﬁed protein. While 1h due to its limited speciﬁcity
towards ATGL and intrinsic toxicity will be less useful as molecular
probe than Atglistatin (B), the SAR studies presented in this manu-
script have provided more insight into the characteristics of theligand binding pocket of ATGL for the ﬁrst time. These studies indi-
cate that the binding pocket of ATGL is rather sensitive to variations
of the investigated chemotype and that bulky substituents are prob-
lematic, suggesting that the binding pocket is rather narrow and
thin, which might suit an enzyme binding lipids quite well.21,22
4. Experimental section
4.1. Materials and methods
Acetonitrile, DMF, ethanol and dimethoxyethane were pur-
chased as absolute solvents from Acros Organics, Fisher Scientiﬁc
and Sigma Aldrich. Toluene (Sigma Aldrich, 99.7%) was dried in
an aluminum oxide column under inert conditions and stored in
Schlenk bottle over 4A molecule sieves under argon atmosphere.
Tetrahydrofuran was dried at reﬂux temperature under argon
atmosphere over sodium until benzophenone indicated dryness
by a deep blue color. 1,2-Dichloroethane was purchased from
ACROS Organics as extra dry solvent (99.8%, AcroSeal) and
directly used in the reactions. All applied starting materials were
commercially available from Alfa Aesar and Sigma Aldrich and
were used as received. Silica gel chromatography was performed
with Acros Organics silica gel 60 (35–70 lM). 1H and 13C NMR
spectra were recorded on a Bruker AVANCE III 300 spectrometer
(1H: 300.36 MHz; 13C: 75.53 MHz) and chemical shifts are refer-
enced to residual protonated solvent signals as internal standard.
Electron impact (EI, 70 eV) HRMS spectra were recorded on
Waters GCT Premier equipped with direct insertion (DI) and GC
(HP GC7890A). Melting points were determined with the appara-
tus ‘Mel-Temp’ from Electrothermal with an integrated micro-
scopical support.
4.2. General synthesis
4.2.1. 1-Nitroso-4-phenylpiperazine
A 100 mL Schlenk tube was charged with 1.00 g (940 lL,
6.17 mmol, 1.00 equiv) 1-phenyl piperazine, 50 mL THF and
1.15 mL (9.57 mmol, 1.55 equiv) tert butylnitrite. The mixture
was reﬂuxed overnight. GC–MS analysis indicated full conversion
of the starting material. The orange solution was transferred to a
one-neck round bottom ﬂask and concentrated in vacuum at a
temperature of 30 C. The crude product was used in the next reac-
tion without further puriﬁcation. Yield: 813.0 mg (74%), light
brown solid. Rf (MeOH/DCM 1:1) 0.55. 1H NMR (300 MHz,
MeOD): d (ppm) = 7.25–7.20 (m, 2H, Ar-H), 6.96 (d, 3J = 7.8 Hz,
2H, Ar-H), 6.84 (t, 3J = 7.2 Hz, 1H, Ar-H), 3.22 (br s, 4H, 2CH2),
2.82 (br s, 4H, 2CH2). 13C NMR (75.5 MHz, MeOD): d
(ppm) = 152.3 (Cq), 130.1 (2CHAr), 121.2 (CHAr), 117.6 (2CHAr),
59.2 (2CH2), 50.1 (2CH2). Mp: 36–38 C.
4.2.2. 4-Phenylpiperazin-1-amine
A 250 mL three-neck round bottom ﬂask with dropping funnel
and reﬂux condenser was dried under vacuum, ﬁlled with nitrogen
and charged with 516 mg (13.6 mmol, 2.20 equiv) LiAlH4 and
25 mL absolute THF. The grey suspension was heated under reﬂux
and a solution of 1.18 g (6.18 mmol, 1.00 equiv) 1-nitroso-4-
phenylpiperazine in 10 mL absolute THF was added dropwise to
the boiling suspension. After complete addition the suspension
was heated under reﬂux for further 3 h. GC–MS analysis showed
full conversion of the starting material. The suspension was hydro-
lyzed according to the n,n,3n-method23 (1 mL water, 1 mL 15%
aqueous NaOH and 3 mL water per 1 g LiAlH4) upon which the
color turned to yellow. The mixture was ﬁltrated through a fritted
funnel, the ﬁlter cake was washed with 10 mL THF and the ﬁltrate
was concentrated under reduced pressure. Final puriﬁcation by
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813.0 mg (74%), light brown solid. Rf (MeOH/DCM 1:1) 0.55. 1H
NMR (300 MHz, MeOD): d (ppm) = 7.25–7.20 (m, 2H, Ar-H), 6.96
(d, 3J = 7.8 Hz, 2H, Ar-H), 6.84 (t, 3J = 7.2 Hz, 1H, Ar-H), 3.22 (br s,
4H, 2CH2), 2.82 (br s, 4H, 2CH2). 13C NMR (75.5 MHz, MeOD): d
(ppm) = 152.3 (Cq), 130.1 (2CHAr), 121.2 (CHAr), 117.6 (2CHAr),
59.2 (2CH2), 50.1 (2CH2). Mp: 36–38 C.
4.2.3. General procedure (GP-1)
An aluminum reaction block was placed on a hotplate stirrer. A
brown 10 mL reaction vessel was charged consecutively with
1.00 equiv 4-phenylpiperazin-1-amine, toluene, 1.00 equiv alde-
hyde and a magnetic stirring bar. The vessel was crimped with a
cap, placed in the preheated (100 C) reaction block and stirred vig-
orously at 100 C. GC–MS analysis indicated full conversion of the
starting material. After cooling to rt the cap was removed, the reac-
tion mixture was transferred into a one-neck round bottom ﬂask
and concentrated under reduced pressure to yield the product.
4.2.4. (E)-4-((4-Phenylpiperazin-1-ylimino)methyl)benzene-
1,2-diol (1a)
According to GP-1: 50.0 mg (282 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 39.0 mg (282 lmol, 1.00 equiv) 3,4-dihydroxy-
benzaldehyde, 1.0 mL toluene, stirring for 2.5 h. temperature of
30 C. Yield: 77.0 mg (92%), brown solid. 1H NMR (300 MHz,
DMSO-d6): d (ppm) = 7.58 (s, 1H, CH@N), 7.26–7.21 (m, 2H, Ar-
H), 7.10 (d, 4J = 1.8 Hz, 1H, Ar-H), 7.00 (t, 3J = 8.1 Hz, 2H, Ar-H),
6.83–6.78 (m, 2H, Ar-H), 6.72 (d, 3J = 8.1 Hz, 1H, Ar-H), 3.30–3.28
(m, 4H, 2CH2), 3.17–3.14 (m, 4H, 2CH2). 13C NMR (75.5 MHz,
DMSO-d6): d (ppm) = 150.6 (Cq), 146.0 (Cq-OH), 145.3 (Cq-OH),
137.4 (CH@N), 128.9 (2CHAr), 127.7 (Cq), 119.1 (CHAr), 118.6
(CHAr), 115.8 (2CHAr), 115.3 (CHAr), 112.1 (CHAr), 51.0 (2CH2),
47.8 (2CH2). Mp: 180 C.
4.2.5. (E)-N-(3,4-Dimethoxybenzylidene)-4-phenylpiperazin-1-
amine (1b)
According to GP-1: 10.0 mg (56.0 lmol, 1.20 equiv) 4-phenylpi-
perazin-1-amine, 7.80 mg (47.0 lmol, 1.00 equiv) 3,4-dimethoxy-
benzaldehyde, 0.5 mL toluene, stirring for 4 h. Yield: 15.3 mg
(>99%), yellow-brown solid. 1H NMR (300 MHz, CDCl3): d
(ppm) = 7.62 (br s, 1H, CH@N), 7.36–7.27 (m, 3H, Ar-H), 7.05–6.98
(m, 3H, Ar-H), 6.93–6.84 (m, 2H, Ar-H), 3.94 (s, 3H, OCH3), 3.90 (s,
3H, OCH3), 3.40–3.38 (m, 4H, 2CH2), 3.34–3.32 (m, 4H, 2CH2). 13C
NMR (75.5 MHz, CDCl3): d (ppm) = 150.9 (2Cq-OCH3), 149.6 (Cq),
149.3 (Cq), 137.3 (CH@N), 129.2 (2CHAr), 120.4 (CHAr), 120.2
(CHAr), 116.5 (2CHAr), 110.7 (CHAr), 107.5 (CHAr), 55.9 (OCH3),
55.8 (OCH3), 51.4 (2CH2), 48.9 (2CH2). Mp: 153–154 C.
4.2.6. (E)-2-Methoxy-5-((4-phenylpiperazin-1-ylimino)methyl)-
phenol (1c)
According to GP-1: 10.0 mg (56.0 lmol, 1.10 equiv) 4-phenylpi-
perazin-1-amine, 7.80 mg (51 lmol, 1.00 equiv) 3-hydrox-
yanisaldehyde, 0.5 mL toluene, stirring for 4.5 h. Yield: 16.0 mg
(>99%), yellow solid. 1H NMR (300 MHz, DMSO-d6): d
(ppm) = 9.06 (s, 1H, OH), 7.62 (s, 1H, CH@N), 7.26–7.21 (m, 2H,
Ar-H), 7.12 (d, 4J = 1.5 Hz, 1H, Ar-H), 7.02–6.79 (m, 5H, Ar-H),
3.77 (s, 3H, OCH3), 3.31–3.29 (m, 4H, 2CH2), 3.20–3.18 (m, 4H,
2CH2). 13C NMR (75.5 MHz, DMSO-d6): d (ppm) = 150.6 (Cq),
148.0 (Cq-OCH3), 146.5 (Cq-OH), 136.7 (CH@N), 129.2 (Cq), 128.9
(2CHAr), 119.1 (CHAr), 118.3 (CHAr), 115.8 (2CHAr), 111.8
(CHAr), 111.7 (CHAr) 55.5 (OCH3), 50.9 (2CH2), 47.8 (2CH2). Mp:
180 C (dec.).
4.2.7. (E)-2-Methoxy-4-((4-phenylpiperazin-1-ylimino)methyl)-
phenol (1d)
According to GP-1: 44.0 mg (249 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 31.3 mg (205 lmol, 1.00 equiv) vanilline, 1.0 mLtoluene, stirring overnight, recrystallization from 2.5 mL toluene.
Yield: 48.0 mg (68%), brown oil. 1H NMR (300 MHz, DMSO-d6): d
(ppm) = 9.18 (s, 1H, OH), 7.66 (s, 1H, CH@N), 7.26–7.16 (m, 3H,
Ar-H), 7.02–6.97 (m, 3H, Ar-H), 6.83–6.75 (m, 2H, Ar-H), 3.78 (s,
3H, OCH3), 3.31–3.19 (m, 8H, 4CH2). 13C NMR (75.5 MHz, DMSO-
d6): d (ppm) = 150.6 (Cq), 147.7 (Cq-OCH3), 147.0 (Cq-OH), 137.2
(CH@N), 128.9 (2CHAr), 128.1 (Cq), 127.7 (CHAr), 119.9 (CHAr),
115.8 (2CHAr), 115.3 (CHAr), 108.6 (CHAr), 55.4 (OCH3), 51.0
(2CH2), 47.8 (2CH2).
4.2.8. (E)-3-((4-Phenylpiperazin-1-ylimino)methyl)phenol (1e)
According to GP-1: 40.0 mg (226 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 27.6 mg (226 lmol, 1.00 equiv) 3-hydroxyben-
zaldehyde, 1.0 mL toluene, stirring overnight. Yield: 32.0 mg
(50%), yellow solid. 1H NMR (300 MHz, DMSO-d6): d (ppm) = 9.41
(s, 1H, OH), 7.64 (s, 1H, CH@N), 7.27–7.21 (m, 2H, Ar-H), 7.15 (t,
3J = 7.8 Hz, 1H, Ar-H), 7.06–6.99 (m, 4H, Ar-H), 6.81 (t, 3J = 7.2 Hz,
1H, Ar-H), 6.68 (dd, 4J = 1.5 Hz, 3J = 7.8 Hz, 1H, Ar-H), 3.32–3.30
(m, 4H, 2CH2), 3.24–3.23 (m, 4H, 2CH2). 13C NMR (75.5 MHz,
DMSO-d6): d (ppm) = 157.4 (Cq-OH), 150.6 (Cq), 137.4 (Cq), 136.1
(CH@N), 129.3 (CHAr), 128.9 (2CHAr), 119.1 (CHAr), 117.3
(CHAr), 115.8 (2CHAr), 115.2 (CHAr), 111.7 (CHAr) 50.6 (2CH2),
47.7 (2CH2). Mp: 190 C (dec.).
4.2.9. (E)-2-((4-Phenylpiperazin-1-ylimino)methyl)phenol (1f)
According to GP-1: 40.0 mg (226 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 27.6 mg (24.0 lL, 226 lmol, 1.00 equiv) 3-hy-
droxybenzaldehyde, 1.0 mL toluene, stirring overnight. Addition
of 14.0 mg (79.0 lmol, 0.35 equiv) 4-phenylpiperazin-1-amine
after 15 h to reach full conversion of the starting material after fur-
ther 6 h stirring. Yield: 84.0 mg (99%), yellow solid. 1H NMR
(300 MHz, CDCl3): d (ppm) = 11.54 (s, 1H, OH), 7.80 (s, 1H,
CH@N), 7.35–7.16 (m, 4H, Ar-H), 7.06–6.88 (m, 5H, Ar-H), 3.41–
3.38 (m, 8H, 4 CH2). 13C NMR (75.5 MHz, CDCl3): d (ppm) = 157.7
(Cq-OH), 141.6 (CH@N), 129.8 (CHAr), 129.7 (2CHAr), 129.2
(2CHAr), 129.0 (Cq), 120.6 (Cq), 119.1 (CHAr), 118.9 (CHAr),
116.7 (CHAr), 116.6 (CHAr), 51.3 (2CH2), 48.7 (2CH2). Mp: 138–
142 C.
4.2.10. (E)-4-((4-Phenylpiperazin-1-ylimino)methyl)phenol (1g)
According to GP-1: 40.0 mg (226 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 27.6 mg (226 lmol, 1.00 equiv) 4-hydroxyben-
zaldehyde, 1.0 mL toluene, stirring overnight. Yield: 63.5 mg
(>99%), beige solid. 1H NMR (300 MHz, DMSO-d6): d (ppm) = 9.59
(s, 1H, OH), 7.66 (s, 1H, CH@N), 7.42 (d, 3J = 8.7 Hz, 2H, Ar-H),
7.25–7.20 (m, 2H, Ar-H), 7.00 (d, 3J = 8.1 Hz, 2H, Ar-H), 6.83–6.74
(m, 3H, Ar-H), 3.30–3.28 (m, 4H, 2CH2), 3.18–3.16 (m, 4H, 2CH2).
13C NMR (75.5 MHz, DMSO-d6): d (ppm) = 157.6 (Cq-OH), 150.6
(Cq), 137.1 (CH@N), 128.9 (2CHAr), 127.3 (2CHAr), 127.2 (Cq),
119.1 (CHAr), 115.7 (2CHAr), 115.3 (2CHAr), 51.0 (2CH2), 47.8
(2CH2). Mp: 192 C (dec.).
4.2.11. (E)-4-(4-Phenylpiperazin-1-ylimino)methylbenzene-1,3-
diol (1h)
According to GP-1: 30.0 mg (169 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 23.4 mg (169 lmol, 1.00 equiv) 2,4-dihydroxy-
benzaldehyde), 1.0 mL toluene, stirring for 2 h. Yield: 51.0 mg
(>99%), brown solid. Rf (MeOH): 0.62. 1H NMR (300 MHz, DMSO-
d6): d (ppm) = 11.60 (s, 1H, OH), 9.72 (br s, 1H, OH), 7.95 (s, 1H,
CH@N), 7.26–7.16 (m, 3H, Ar-H), 7.00 (d, 3J = 8.1 Hz, 2H, Ar-H),
6.81 (t, 3J = 7.2 Hz, 1H, Ar-H), 6.32 (dd, 3J = 8.1 Hz, 4J = 2.1 Hz, 1H,
Ar-H), 6.25 (d, 4J = 2.1 Hz, 1H, Ar-H), 3.33–3.30 (m, 4H, 2CH2),
3.18–3.15 (m, 4H, 2CH2). 13C NMR (75.5 MHz, DMSO-d6): d
(ppm) = 159.0 (Cq-OH), 158.6 (Cq-OH), 150.5 (Cq), 142.3 (CH@N),
130.7 (CHAr), 128.9 (2CHAr), 119.2 (CHAr), 115.8 (2CHAr), 111.4
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183–184 C.
4.2.12. (E)-4-Phenyl-N-(4-propoxybenzylidene)piperazin-1-
amine (1i)
According to GP-1: 30.0 mg (169 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 27.7 mg (27.0 lL, 169 lmol, 1.00 equiv) 4-
propoxybenzaldehyde, 1.0 mL toluene, stirring overnight. Yield:
40.0 mg (71%), light yellow solid. 1H NMR (300 MHz, CDCl3): d
(ppm) = 7.65 (s, 1H, CH@N), 7.57 (d, 3J = 8.7 Hz, 2H, Ar-H), 7.33–
7.28 (m, 2H, Ar-H), 6.99 (d, 3J = 8.1 Hz, 2H, Ar-H), 6.93–6.88 (m,
3H, Ar-H), 3.94 (t, 3J = 6.6 Hz, 2H, OCH2), 3.41–3.38 (m, 4H,
2CH2), 3.33–3.30 (m, 4H, 2CH2), 1.82 (sext, 3J = 6.9 Hz, 3J = 7.2 Hz,
2H, CH2), 1.05 (t, 3J = 7.2 Hz, 3H, CH3). 13C NMR (75.5 MHz,
CDCl3): d (ppm) = 159.6 (Cq-OCH2), 150.9 (Cq), 137.7 (CH@N),
129.2 (2CHAr), 128.6 (Cq), 127.6 (2CHAr), 120.2 (CHAr), 116.5
(2CHAr), 114.6 (2CHAr), 69.5 (OCH2), 51.5 (2CH2), 48.9 (2CH2),
22.6 (CH2), 10.5 (CH3). Mp: 184–185 C.
4.2.13. (E)-N-(4-Phenoxybenzylidene)-4-phenylpiperazin-1-
amine (1j)
According to GP-1: 40.0 mg (226 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 44.7 mg (226 lmol, 1.00 equiv) 4-phenoxyben-
zaldehyde, 1.0 mL toluene, stirring overnight. Yield: 76.0 mg
(94%), yellow-brown solid. 1H NMR (300 MHz, CDCl3): d
(ppm) = 7.66 (s, 1H, CH@N), 7.61 (d, 3J = 8.7 Hz, 2H, Ar-H), 7.38–
7.28 (m, 4H, Ar-H), 7.12 (t, 3J = 7.2 Hz, 1H, Ar-H), 7.02 (m, 6H, Ar-
H), 6.92 (t, 3J = 7.2 Hz, 1H, Ar-H), 3.41–3.34 (m, 8H, 4 CH2). 13C
NMR (75.5 MHz, CDCl3): d (ppm) = 157.6 (Cq), 156.9 (Cq), 150.9
(Cq), 136.4 (CH@N), 131.2 (Cq), 129.8 (2CHAr), 129.2 (2CHAr),
127.7 (2CHAr), 123.4 (2CHAr), 120.3 (CHAr), 119.0 (2CHAr), 118.8
(2CHAr), 116.6 (CHAr), 51.3 (2CH2), 48.9 (2CH2). Mp: 161–164 C.
HRMS (EI+): m/z: calcd for C23H23ON3 [M]+: 357.1841; found
357.1844.
4.2.14. (E)-4-Phenyl-N-(2,4,5-trimethoxybenzyliden)piperazin-
1-amine (1k)
According to GP-1: 30.0 mg (169 lmol, 2.00 equiv) 4-phenylpi-
perazin-1-amine, 33.1 mg (169 lmol, 1.00 equiv) 2,4,5-
trimethoxybenzaldehyde, 1.0 mL toluene, stirring overnight.
Addition of 3.0 mg (15.0 lmol, 0.09 equiv) 4-phenylpiperazin-1-
amine after 18 h to reach full conversion of the starting material
after further stirring over a second night. Yield: 55.0 mg (83%), yel-
low-orange solid. 1H NMR (300 MHz, CDCl3): d (ppm) = 8.00 (br s,
1H, CH@N), 7.46 (s, 1H, Ar-H), 7.34–7.27 (m, 3H, Ar-H), 6.99 (d,
3J = 7.8 Hz, 2H, Ar-H), 6.50 (s, 1H, arom.H), 3.91 (s, 3H, OCH3),
3.90 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.41–3.38 (m, 4H, 2CH2),
3.34–3.31 (m, 4H, 2CH2). 13C NMR (75.5 MHz, CDCl3): d
(ppm) = 152.1 (Cq-OCH3), 151.0 (Cq-OCH3), 150.3 (Cq-OCH3),
143.7 (CH@N), 129.1 (2CHAr), 128.2 (Cq), 120.1 (CHAr), 116.6
(Cq), 116.5 (2CHAr), 107.9 (CHAr), 97.3 (CHAr), 56.7 (OCH3), 56.2
(OCH3), 56.0 (OCH3), 51.5 (2CH2), 48.9 (2CH2). Mp: 153–156 C.
4.2.15. (E)-4-Phenyl-N-(3,4,5-trimethoxybenzylidene)piperazin-
1-amine (1l)
According to GP-1: 30.0 mg (169 lmol, 2.00 equiv) 4-phenylpi-
perazin-1-amine, 33.1 mg (169 lmol, 1.00 equiv) 3,4,5-
trimethoxybenzaldehyde, 1.0 mL toluene, stirring overnight.
Addition of 2.00 mg (10.0 lmol, 0.06 equiv) 4-phenylpiperazin-1-
amine after 18 h to reach full conversion of the starting material
after further stirring over a second night. Yield: 28.0 mg (44%), yel-
low solid. 1H NMR (300 MHz, CDCl3): d (ppm) = 7.93 (s, 1H, CH@N),
7.70–7.64 (m, 3H, Ar-H), 7.37 (d, 3J = 8.1 Hz, 2H, Ar-H), 7.33–7.28
(m, 2H, Ar-H), 4.28 (s, 6H, 2OCH3), 4.24 (s, 3H, OCH3), 3.78–3.71
(m, 8H, 4 CH2). 13C NMR (75.5 MHz, CDCl3): d (ppm) = 153.4
(2Cq-OCH3), 150.9 (Cq-OCH3), 138.5 (Cq), 136.4 (CH@N), 131.7(Cq), 129.2 (2CHAr), 120.3 (CHAr), 116.6 (2CHAr), 103.2 (CHAr),
60.9 (OCH3), 56.1 (2OCH3), 51.2 (2CH2), 48.9 (2CH2). Mp: 93–98 C.
4.2.16. (E)-N-(3,4-Diﬂuorobenzylidene)-4-phenylpiperazin-1-
amine (1m)
According to GP-1: 250 mg (1.41 mmol, 2.00 equiv) 4-phenylpi-
perazin-1-amine, 100 mg (78.0 lL, 706 lmol, 1.00 equiv) 3,4-di-
ﬂuorobenzaldehyde, 3.0 mL toluene, stirring overnight. Yield:
189.8 g (90%), yellow solid. 1H NMR (300 MHz, CDCl3): d
(ppm) = 7.52–7.43 (m, 2H, CH@N, Ar-H), 7.31–7.24 (m, 3H, Ar-H),
7.16–7.07 (m, 1H, Ar-H), 6.98 (d, 3J = 7.8 Hz, 2H, Ar-H), 6.90 (t,
3J = 7.2 Hz, 1H, Ar-H), 3.37–3.36–3.34 (m, 8H, 4CH2). 13C NMR
(75.5 MHz, CDCl3): d (ppm) = 152.4, 152.2 (3JC–F = 16.5 Hz, Cq),
151.8, 149.1 (1JC–F = 203.2 Hz, Cq-F), 150.8, 148.7 (1JC–F = 161.2 Hz,
Cq-F), 133.6 (CH@N), 133.5 (Cq), 129.2 (2CHAr), 122.5, 122.4,
122.4, 122.3 (3JC–F = 6.2 Hz, 4JC–F = 3.2 Hz, CHAr), 120.4 (CHAr),
117.3, 117.1 (2JC–F = 17.6 Hz, CHAr), 116.6 (2CHAr), 114.2, 114.0
(2JC–F = 18.2 Hz, CHAr), 51.0 (2CH2), 48.9 (2CH2). Mp: 152–154 C.
HRMS (EI+): m/z: calcd for C17H17N3F2 [M]+: 301.1391; found
301.1395.
4.2.17. (E)-N-(3,4-Dichlorobenzylidene)-4-phenylpiperazin-1-
amine (1n)
According to GP-1: 50.0 mg (282 lmol, 2.00 equiv) 4-phenylpi-
perazin-1-amine, 25.0 mg (141 lmol, 1.00 equiv) 3,4-dichloroben-
zaldehyde, 1.0 mL toluene, stirring overnight. Addition of another
14.0 mg (80.0 lmol, 0.60 equiv) 4-phenylpiperazin-1-amine after
16 h to reach full conversion of the starting material after further
stirring over a second night. Yield: 67.0 mg (90%), light yellow
solid. 1H NMR (300 MHz, CDCl3): d (ppm) = 7.73 (s, 1H, CH@N),
7.47 (s, 1H, Ar-H), 7.42 (s, 2H, Ar-H), 7.34–7.28 (m, 2H, Ar-H),
7.00 (d, 3J = 8.1 Hz, 2H, Ar-H), 6.95–6.90 (m, 1H, Ar-H), 3.38 (s,
8H, 4CH2). 13C NMR (75.5 MHz, CDCl3): d (ppm) = 150.7 (Cq),
136.3 (CH@N), 133.0 (Cq-Cl), 132.8 (Cq), 131.6 (Cq-Cl), 130.4
(CHAr), 129.2 (2CHAr), 127.5 (CHAr), 125.2 (CHAr), 120.5 (CHAr),
116.7 (2CHAr), 50.8 (2CH2), 49.0 (2CH2). Mp: 176–178 C.
4.2.18. (E)-N-(2,4-Dichlorobenzylidene)-4-phenylpiperazin-1-
amine (1o)
According to GP-1: 50.0 mg (282 lmol, 2.00 equiv) 4-phenylpi-
perazin-1-amine, 25.0 mg (141 lmol, 1.00 equiv) 2,4-dichloroben-
zaldehyde, 1.0 mL toluene, stirring overnight. Addition of another
14.0 mg (80.0 lmol, 0.60 equiv) 4-phenylpiperazin-1-amine after
16 h to reach full conversion of the starting material after further
stirring over a second night. Yield: 71.0 mg (95%), yellow solid.
1H NMR (300 MHz, CDCl3): d (ppm) = 7.85 (d, 3J = 8.7 Hz, 1H, Ar-
H), 7.77 (s, 1H, CH@N), 7.29 (d, 4J = 2.1 Hz, 1H, Ar-H), 7.25–7.13
(m, 3H, Ar-H), 6.94–6.91 (m, 2H, Ar-H), 6.85 (t, 3J = 7.2 Hz, 1H,
Ar-H), 3.33 (s, 8H, 4 CH2). 13C NMR (75.5 MHz, CDCl3): d
(ppm) = 150.8 (Cq), 133.9 (Cq-Cl), 133.1 (Cq), 132.1 (Cq-Cl), 130.9
(CH@N), 129.3 (CHAr), 129.2 (2CHAr), 127.3 (CHAr), 127.1
(CHAr), 120.4 (CHAr), 116.7 (2CHAr), 50.9 (2CH2), 48.9 (2CH2).
Mp: 113–115 C.
4.2.19. (E)-N-(2-Nitrobenzylidene)-4-phenylpiperazin-1-amine
(1p)
According to GP-1: 40.0 mg (226 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 26.2 mg (226 lmol, 1.00 equiv) 2-nitroben-
zaldehyde, 1.0 mL toluene, stirring overnight. Addition of 3.40 mg
(22.0 lmol, 0.10 equiv) 2-nitrobenzaldehyde after 20 h to reach
full conversion of the starting material after further 3 h stirring.
Yield: 60.0 mg (97%), yellow-brown solid. 1H NMR (300 MHz,
CDCl3): d (ppm) = 8.15–8.13 (m, 1H, Ar-H), 8.10 (s, 1H, CH@N),
8.00 (d, 3J = 8.1 Hz, 1H, Ar-H), 7.58 (t, 3J = 7.8 Hz, 1H, Ar-H), 7.41–
7.28 (m, 3H, Ar-H), 7.01 (d, 3J = 7.8 Hz, 2H, Ar-H), 6.92 (t,
3J = 7.2 Hz, 1H, Ar-H), 3.45–3.39 (m, 8H, 4CH2). 13C NMR
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(CH@N), 131.1 (Cq), 130.2 (CHAr), 129.2 (2CHAr), 127.9 (CHAr),
127.5 (CHAr), 124.6 (CHAr), 120.4 (CHAr), 116.6 (2CHAr), 50.8
(2CH2), 48.8 (2CH2). Mp: 103–106 C.
4.2.20. (E)-N-(2-Bromobenzylidene)-4-phenylpiperazin-1-amine
(1q)
According to GP-1: 40.0 mg (226 lmol, 1.20 equiv) 4-phenylpi-
perazin-1-amine, 34.8 mg (22.0 lL, 118 lmol, 1.00 equiv) 2-bro-
mobenzaldehyde, 1.0 mL toluene, stirring overnight. Yield:
69.0 mg (89%), yellow-orange solid. 1H NMR (300 MHz, CDCl3): d
(ppm) = 7.95 (dd, 3J = 7.8 Hz, 4J = 1.5 Hz, 1H, Ar-H), 7.90 (s, 1H,
CH@N), 7.53 (dd, 3J = 8.1 Hz, 4J = 0.9 Hz, 1H, Ar-H), 7.33–7.28 (m,
3H, Ar-H), 7.16–7.10 (m, 1H, Ar-H), 7.00 (d, 3J = 7.8 Hz, 2H, Ar-H),
6.92 (t, 3J = 7.5 Hz, 1H, Ar-H), 3.41 (s, 8H, 4 CH2). 13C NMR
(75.5 MHz, CDCl3): d (ppm) = 150.9 (Cq), 135.0 (CH@N), 134.8
(Cq), 132.8 (CHAr), 129.3 (CHAr), 129.2 (2CHAr), 127.5 (CHAr),
126.7 (CHAr), 123.2(Cq-Br), 120.3 (CHAr), 116.6 (2CHAr), 51.0
(2CH2), 48.9 (2CH2). Mp: 88–90 C.
4.2.21. (E)-3-((4-Phenylpiperazin-1-ylimino)methyl)benzonitrile
(1r)
According to GP-1: 40.0 mg (226 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 30.0 mg (226 lmol, 1.00 equiv) 3-formylben-
zonitrile, 1.0 mL toluene, stirring for 6 h. Yield: 67.0 mg (99%),
yellow solid. 1H NMR (300 MHz, CDCl3): d (ppm) = 7.91 (s, 1H,
CH@N), 7.82 (dd, 3J = 7.8 Hz, 4J = 1.2 Hz, 1H, Ar-H), 7.55–7.52 (m,
2H, Ar-H), 7.44 (t, 3J = 7.8 Hz, 1H, Ar-H), 7.33–7.28 (m, 2H, Ar-H),
7.99 (d, 3J = 7.8 Hz, 2H, Ar-H), 6.92 (t, 3J = 7.2 Hz, 1H, Ar-H), 3.39
(s, 8H, 4 CH2). 13C NMR (75.5 MHz, CDCl3): d (ppm) = 150.8 (Cq),
137.5 (CH@N), 132.6 (CHAr), 131.0 (Cq), 130.0 (CHAr), 129.4
(CHAr), 129.3 (CHAr), 129.2 (2CHAr), 120.4 (CHAr), 118.8 (CN),
116.7 (2CHAr), 112.7 (Cq-CN), 50.8 (2CH2), 48.9 (2CH2). Mp:
140–142 C. HRMS (EI+): m/z: calcd for C18H18N4 [M]+: 290.1531;
found 290.1539.
4.2.22. (E)-4-((4-Phenylpiperazin-1-ylimino)methyl)benzonitrile
(1s)
According to GP-1: 40.0 mg (226 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 29.6 mg (226 lmol, 1.00 equiv) 4-formylben-
zonitrile, 1.0 mL toluene, stirring overnight. Yield: 60.0 mg (92%),
yellow-orange solid. 1H NMR (300 MHz, CDCl3): d (ppm) = 7.69
(d, 3J = 8.4 Hz, 2H, Ar-H), 7.61 (d, 3J = 8.4 Hz, 2H, Ar-H), 7.52 (s,
1H, CH@N), 7.33–7.28 (m, 2H, Ar-H), 6.99 (d, 3J = 7.8 Hz, 2H, Ar-
H), 6.92 (t, 3J = 7.2 Hz, 1H, Ar-H), 3.40 (s, 8H, 4 CH2). 13C NMR
(75.5 MHz, CDCl3): d (ppm) = 150.8 (Cq), 140.6 (Cq), 132.5
(CH@N), 132.3 (2CHAr), 129.2 (2CHAr), 126.2 (2CHAr), 120.5
(CHAr), 119.1 (CN),116.7 (2CHAr), 110.8 (Cq-CN), 50.7 (2CH2),
48.9 (2CH2). Mp: 165–169 C. HRMS (EI+): m/z: calcd for
C18H18N4 [M]+: 290.1531; found 290.1519.
4.2.23. (E)-N-(4-Methylbenzylidene)-4-phenylpiperazin-1-amine
(1t)
According to GP-1: 40.0 mg (226 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 27.0 mg (27.0 lL, 226 lmol, 1.00 equiv) p-tolyl-
benzaldehyde, 1.0 mL toluene, stirring overnight. Yield: 64.0 mg
(99%), light yellow solid. 1H NMR (300 MHz, CDCl3): d
(ppm) = 7.66 (s, 1H, CH@N), 7.53 (d, 3J = 8.1 Hz, 2H, Ar-H), 7.30
(dd, 3J = 8.4 Hz, 3J = 7.5 Hz, 2H, Ar-H), 7.17 (d, 3J = 7.8 Hz, 2H, Ar-
H), 7.00 (d, 3J = 8.1 Hz, 2H, Ar-H), 6.91 (t, 3J = 7.5 Hz, 1H, Ar-H),
3.41–3.34 (m, 8H, 4 CH2). 13C NMR (75.5 MHz, CDCl3): d
(ppm) = 150.9 (Cq), 138.4 (C-CH3), 137.3 (CH@N), 133.2 (Cq),
129.3 (2CHAr), 129.2 (2CHAr), 126.2 (2CHAr), 120.3 (CHAr),
116.6 (2CHAr), 51.3 (2CH2), 48.9 (2CH2), 21.3 (CH3). Mp: 184–
186 C.4.2.24. (E)-N-(4-(Dimethylamino)benzylidene)-4-phenylpi-
perazin-1-amine (1u)
According to GP-1: 40.0 mg (226 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 34.0 mg (226 lmol, 1.00 equiv) 4-dimethy-
laminobenzaldehyde, 1.0 mL toluene, stirring overnight. Addition
of another 4.00 mg (23.0 lmol, 0.10 equiv) 4-phenylpiperazin-1-
amine after 18 h to reach full conversion of the starting material
after further 2 h stirring. Yield: 43.0 mg (61%), light yellow solid.
1H NMR (300 MHz, CDCl3): d (ppm) = 7.68 (br s, 1H, CH@N), 7.53
(d, 3J = 8.7 Hz, 2H, Ar-H), 7.33–7.28 (m, 2H, Ar-H), 7.00 (d,
3J = 8.1 Hz, 2H, Ar-H), 6.90 (t, 3J = 7.2 Hz, 1H, Ar-H), 6.71 (d,
3J = 8.7 Hz, 2H, Ar-H), 3.40–3.38 (m, 4H, 2CH2), 3.31–3.29 (m, 4H,
2CH2), 2.99 (s, 6H, 2CH3). 13C NMR (75.5 MHz, CDCl3): d
(ppm) = 151.0 (Cq-N), 150.8 (Cq), 139.5 (CH@N), 129.1 (2CHAr),
127.6 (2CHAr), 124.2 (Cq), 120.0 (CHAr), 116.4 (2CHAr), 112.1
(2CHAr), 51.8 (2CH2), 48.9 (2CH2), 40.4 (2CH3). Mp: 190 C (dec.).
4.2.25. (E)-N-(4-((4-Phenylpiperazin-1-ylimino)methyl)phenyl)-
acetamide (1v)
According to GP-1: 30.0 mg (169 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 27.5 mg (169 lmol, 1.00 equiv) 4-acetamidoben-
zaldehyde, 1.0 mL toluene, stirring overnight. Yield: 54.0 mg (96%),
yellow solid. 1H NMR (300 MHz, DMSO-d6): d (ppm) = 10.00 (s, 1H,
NH), 7.68 (s, 1H, CH@N), 7.61–7.50 (m, 4H, Ar-H), 7.26–7.21 (m,
2H, Ar-H), 7.00 (d, 3J = 8.1 Hz, 2H, Ar-H), 6.81 (t, 3J = 7.2 Hz, 1H,
Ar-H), 3.32–3.30 (m, 4H, 2CH2), 3.23–3.21 (m, 4H, 2CH2), 2.05 (s,
3H, CH3). 13C NMR (75.5 MHz, DMSO-d6): d (ppm) = 168.1 (C@O),
150.6 (Cq), 139.1 (Cq-NH), 136.0 (CH@N), 130.9 (Cq), 128.8
(2CHAr), 126.2 (2CHAr), 119.1 (CHAr), 118.8 (2CHAr), 115.8
(2CHAr), 50.7 (2CH2), 47.7 (2CH2), 23.9 (CH3). Mp: 229–232 C.
HRMS (EI+): m/z: calcd for C19H22ON4 [M]+: 322.1794; found
322.1795.
4.2.26. (E)-2-(Methyl(4-((4-phenylpiperazin-1-ylimino)methyl)-
phenyl)amino)ethanol (1w)
According to GP-1: 30.0 mg (169 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 30.3 mg (169 lmol, 1.00 equiv) N-methyl-N-(2-
hydroxyethyl)-4-aminobenzaldehyde, 1.0 mL toluene, stirring
overnight. Yield: 48.0 mg (84%), light yellow solid. 1H NMR
(300 MHz, DMSO-d6): d (ppm) = 7.66 (s, 1H, CH@N), 7.42 (d,
3J = 8.7 Hz, 2H, Ar-H), 7.23 (t, 3J = 8.1 Hz, 2H, Ar-H), 6.99 (d,
3J = 8.1 Hz, 2H, Ar-H), 6.81 (t, 3J = 7.2 Hz, 1H, Ar-H), 6.68 (d,
3J = 9.0 Hz, 2H, Ar-H), 4.68 (t, 3J = 5.1 Hz, OH), 3.58–3.52 (m, 2H,
CH2), 3.43–3.39 (m, 2H, CH2), 3.32–3.38 (m, 4H, 2CH2), 3.17–3.14
(m, 4H, 2CH2), 2.95 (s, 3H, N-CH3). 13C NMR (75.5 MHz, DMSO-
d6): d (ppm) = 150.6 (Cq-N), 149.2 (Cq), 138.0 (CH@N), 128.8
(2CHAr), 127.1 (2CHAr), 123.4 (Cq), 119.0 (CHAr), 115.7 (2CHAr),
111.3 (2CHAr), 58.0 (N-CH2), 54.0 (O-CH2), 51.2 (2CH2), 47.8
(2CH2), 38.5 (NCH3). Mp: 202–204 C. HRMS (EI+): m/z: calcd for
C20H26ON4 [M]+: 338.2107; found 338.2117.
4.2.27. (E)-N-(Benzo[d][1,3]dioxol-5-ylmethylen)-4-phenylpi-
perazin-1-amine (1x)
According to GP-1: 38.0 mg (215 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 1.0 mL toluene, 32.2 mg (215 lmol, 1.00 equiv)
benzo[d][1,3]-dioxol-5-carbaldehyde. Stirring at 100 C for 4 h.
Final puriﬁcation by recrystallization from 1.0 mL toluene pro-
duced the pure product. Yield: 40.0 mg (67%), orange-brown solid.
1H NMR (300 MHz, DMSO-d6): d (ppm) = 7.67 (s, 1H, CH@N), 7.26–
7.21 (m, 2H, Ar-H), 7.18–7.17 (m, 1H, Ar-H), 7.05–6.99 (m, 3H, Ar-
H), 6.92–6.90 (m, 1H, Ar-H), 6.83–6.79 (m, 1H, Ar-H), 6.03 (s, 2H,
CH2), 3.31 (m, 4H, 2CH2), 3.21 (m, 4H, 2CH2). 13C NMR
(75.5 MHz, DMSO-d6): d (ppm) = 150.6 (Cq), 147.6 (Cq), 147.2
(Cq), 136.1 (CH@N), 130.7 (Cq), 128.8 (2CHAr), 121.0 (CHAr),
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(CH2), 50.8 (2CH2), 47.7 (2CH2). Mp: 125–129 C.
4.2.28. (E)-N-((2,3-Dihydrobenzol[b][1,4]dioxin-6-yl)methylen)-
4-phenylpiperazin-1-amine (1y)
According to GP-1: 50.0 mg (282 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 46.0 mg (282 lmol, 1.00 equiv) 1,4-benzodiox-
an-6-carboxaldehyde, 1.0 mL toluene, stirring overnight. Yield:
87.0 mg (95%), light brown solid. 1H NMR (300 MHz, DMSO-d6): d
(ppm) = 7.63 (s, 1H, CH@N), 7.26–7.21 (m, 2H, Ar-H), 7.09–7.06
(m, 2H, Ar-H), 7.01–6.98 (m, 2H, Ar-H), 6.86–6.79 (m, 2H, Ar-H),
4.24 (s, 4H, 2CH2), 3.32–3.29 (m, 4H, 2CH2), 3.21–3.17 (s, 4H,
2CH2). 13C NMR (75.5 MHz, DMSO-d6): d (ppm) = 150.6 (Cq-O),
143.5 (Cq), 143.3 (Cq-O), 135.9 (CH@N), 129.7 (Cq), 128.8
(2CHAr), 119.1 (CHAr), 117.0 (CHAr), 115.8 (2CHAr), 114.0
(CHAr), 64.0 (2CH2), 50.8 (2CH2), 47.7 (2CH2). Mp: 186–187 C.
HRMS (EI+): m/z: calcd for C19H21O2N3 [M]+: 323.1634; found
323.1644.
4.2.29. (E)-5-((4-Phenylpiperazin-1-ylimino)methyl)-1H-benzo-
[d]imidazol-2(3H)-one (1z)
According to GP-1: 65.6 mg (370 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 1.0 mL toluene, 60.0 mg (370 lmol, 1.00 equiv)
2-oxo-2,3-dihydro-1H-benzimidazol-5-carbaldehyde. Stirring at
100 C for 5 h. Additional 6.10 mg (34.0 lmol, 0.09 equiv) 4-phe-
nylpiperazin-1-amine and further stirring for 3 h were necessary
to reach full conversion of aldehyde. Yield: 119.0 mg (99%), color-
less solid. Rf (EtOAc/MeOH 30:1): 0.27. 1H NMR (300 MHz, DMSO-
d6): d (ppm) = 10.64 (br s, 2H, 2NH), 7.73 (s, 1H, CH@N), 7.26–7.21
(m, 3H, Ar-H), 7.18–7.14 (m, 1H, Ar-H), 7.01 (d, 3J = 8.1 Hz, 2H, Ar-
CH), 6.90 (d, 3J = 8.1 Hz, 1H, Ar-H), 6.81 (t, 3J = 7.2 Hz, 1H, Ar-H),
3.33–3.30 (m, 4H, 2CH2), 3.22–3.20 (m, 4H, 2CH2). 13C NMR
(75.5 MHz, DMSO-d6): d (ppm) = 155.4 (C@O), 150.6 (Cq), 137.4
(CH@N), 130.0 (Cq), 129.1 (Cq), 128.9 (2CHAr), 119.9 (CHAr),
119.1 (CHAr), 115.8 (2CHAr), 115.3 (Cq), 108.2 (CHAr), 104.9
(CHAr), 50.9 (2CH2), 47.8 (2CH2). Mp: 320–330 C (dec.). HRMS
(EI+): m/z: calcd for C18H19ON5 [M]+: 321.1590; found 321.1606.
4.2.30. (E)-N-Pentyliden-4-phenylpiperazin-1-amine (2a)
According to GP-1: 50.0 mg (282 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 24.3 mg (30.0 lL, 282 lmol, 1.00 equiv) valer-
aldehyde, 1.0 mL toluene, stirring overnight. Yield: 65.0 mg (94%),
orange oil. 1H NMR (300 MHz, CDCl3): d (ppm) = 7.31–7.25 (m,
2H, Ar-H), 7.05 (t, 3J = 5.4 Hz, 1H, CH@N), 6.96 (d, 3J = 7.8 Hz, 2H,
Ar-H), 6.88 (t, 3J = 7.2 Hz, 1H, Ar-H), 3.34 (t, 3J = 5.1 Hz, 4H, 2CH2),
3.12 (t, 3J = 5.1 Hz, 4H, 2CH2), 2.28 (q, 3J = 7.2 Hz, 2H, CH2), 1.55–
1.32 (m, 4H, 2CH2), 0.93 (t, 3J = 7.2 Hz, 3H, CH3). 13C NMR
(75.5 MHz, CDCl3): d (ppm) = 150.9 (CH@N), 143.5 (Cq), 129.1
(2CHAr), 120.1 (CHAr), 116.4 (2CHAr), 51.9 (2CH2), 48.8 (2CH2),
32.8 (CH2), 29.5 (CH2), 22.3 (CH2), 13.9 (CH3). HRMS (EI+): m/z:
calcd for C15H23N3 [M]+: 245.1892; found 245.1885.
4.2.31. (E)-N-((E)-Hex-2-enyliden)-4-phenylpiperazin-1-amine
(2b)
According to GP-1: 51.1 mg (289 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 28.3 mg (30.0 lL, 289 lmol, 1.00 equiv) trans-2-
hexen-1-al, 3.0 mL toluene, stirring for 3 h. Yield: 74.3 mg (>99%),
brown solid. 1H NMR (300 MHz, CDCl3): d (ppm) = 7.38 (d,
3J = 8.7 Hz, 1H, CH@N), 7.31–7.27 (m, 2H, Ar-H), 6.98 (d,
3J = 7.8 Hz, 2H, Ar-H), 6.89 (t, 3J = 7.2 Hz, 1H, Ar-H), 6.28–6.20 (m,
1H, CH), 5.99–5.89 (m, 1H, CH), 3.36–3.33 (m, 4H, 2CH2), 3.22–
3.19 (m, 4H, 2CH2), 2.20–2.12 (m, 2H, CH2), 1.47 (m, 2H, CH2),
0.93 (t, 3J = 7.2 Hz, 3H, CH3). 13C NMR (75.5 MHz, CDCl3): d
(ppm) = 150.9 (Cq), 140.6 (CH), 138.4 (CH@N), 129.1 (2CHAr),
128.7 (CH), 120.1 (CHAr), 116.5 (2CHAr), 51.3 (2CH2), 48.8(2CH2), 34.7 (CH2), 22.1 (CH2), 13.6 (CH3). Mp: 48 C. HRMS (EI+):
m/z: calcd for C16H23N3 [M]+: 257.1892; found 257.1898.
4.2.32. (E)-N-(Cyclohexylmethylen)-4-phenylpiperazin-1-amine
(2c)
According to GP-1: 40.0 mg (226 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 25.1 mg (27.1 lL, 226 lmol, 1.00 equiv) cyclo-
hexanecarboxaldehyde, 1.0 mL toluene, stirring for 4 h. Yield:
60.0 mg (98%), yellow-brown solid. 1H NMR (300 MHz, CDCl3): d
(ppm) = 7.31–7.24 (m, 3H, Ar-H, CH@N), 6.96 (d, 3J = 8.1 Hz, 2H,
Ar-H), 6.90–6.86 (m, 1H, Ar-H), 3.35–3.32 (m, 4H, 2CH2), 3.12–
3.08 (m, 4H, 2CH2), 2.25–2.21 (m, 1H, CH), 1.82–1.66 (m, 5H,
CH2, CH), 1.35–1.16 (m, 5H, CH2, CH). 13C NMR (75.5 MHz,
CDCl3): d (ppm) = 150.9 (CH@N), 147.4 (Cq), 129.1 (2CHAr), 120.0
(CHAr), 116.4 (2CHAr), 51.8 (2CH2), 48.8 (2CH2), 41.4 (CH), 31.0
(2CH2), 26.0 (CH2), 25.6 (2CH2). Mp: 69–71 C. HRMS (EI+): m/z:
calcd for C17H25N3 [M]+: 271.2048; found 271.2058.
4.2.33. (E)-N-(Cyclohexenylmethylen)-4-phenylpiperazin-1-amine
(2d)
According to GP-1: 40.0 mg (226 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 24.9 mg (25.8 lL, 226 lmol, 1.00 equiv) 1-cyclo-
hexene-1-carboxaldehyde, 1.0 mL toluene, stirring for 4 h. Yield:
57.0 mg (94%), yellow-brown solid. 1H NMR (300 MHz, CDCl3): d
(ppm) = 7.34 (s, 1H, CH@N), 7.31–7.26 (m, 2H, Ar-H), 6.97 (d,
3J = 8.1 Hz, 2H, Ar-H), 6.88 (t, 3J = 7.2 Hz, 1H, Ar-H), 5.92 (t,
3J = 3.9 Hz, 1H, CH), 3.36–3.33 (m, 4H, 2CH2), 3.20–3.17 (m, 4H,
2CH2), 2.31 (br s, 2H, CH2), 2.19 (br s, 2H, CH2), 1.67–1.65 (m,
4H, 2CH2). 13C NMR (75.5 MHz, CDCl3): d (ppm) = 151.9 (Cq),
142.5 (CH@N), 136.3 (Cq), 132.3 (CH), 129.1 (2CHAr), 120.0
(CHAr), 116.4 (2CHAr), 51.5 (2CH2), 48.9 (2CH2), 25.9 (CH2), 23.8
(CH2), 22.7 (CH2), 22.2 (CH2). Mp: 118–120 C. HRMS (EI+): m/z:
calcd for C17H23N3 [M]+: 269.1892; found 269.1899.
4.2.34. (E)-4-Phenyl-N-(pyridine-2-ylmethylen)piperazin-1-amine
(2e)
According to GP-1: 50.0 mg (282 lmol, 2.00 equiv) 4-phenylpi-
perazin-1-amine, 30.2 mg (27.0 lL, 282 lmol, 1.00 equiv) 2-
pyridinecarboxaldehyde, 1.0 mL toluene, stirring for 4.5 h.
Additional 3.0 mg (28.0 lmol, 0.10 equiv) 2-pyridinecarboxalde-
hyde and further stirring overnight were necessary to reach full
conversion of amine. Yield: 65.0 mg (87%), brown solid. 1H NMR
(300 MHz, CDCl3): d (ppm) = 8.38–8.36 (m, 1H, Ar-H), 7.71–7.69
(m, 1H, Ar-H), 7.51 (s, 1H, CH@N), 7.15–7.08 (m, 3H, Ar-H), 7.00–
6.97 (m, 1H, Ar-H), 6.81 (d, 3J = 7.8 Hz, 2H, Ar-H), 6.73 (t,
3J = 7.2 Hz, 1H, Ar-H), 3.23–3.20 (m, 8H, 4CH2). 13C NMR
(75.5 MHz, CDCl3): d (ppm) = 155.2 (Cq), 150.9 (Cq), 149.0
(CHAr), 136.3 (CH@N), 135.9 (CHAr), 129.2 (2CHAr), 122.4
(CHAr), 120.3 (CHAr), 119.3 (CHAr), 116.6 (2CHAr), 50.7 (2CH2),
48.9 (2CH2). Mp: 117-119 C.
4.2.35. (E)-4-Phenyl-N-(pyridine-3-ylmethylen)piperazin-1-amine
(2f)
According to GP-1: 50.0 mg (282 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 30.2 mg (26.5 lL, 282 lmol, 1.00 equiv) 3-
pyridinecarboxaldehyde, 1.0 mL toluene, stirring for 5 h. Yield:
75.0 mg (99%), red-brown solid. 1H NMR (300 MHz, CDCl3): d
(ppm) = 8.75 (d, 4J = 1.8 Hz, 1H, Ar-H), 8.51–8.49 (m, 1H, Ar-H),
8.02–7.98 (m, 1H, Ar-H), 7.56 (s, 1H, CH@N), 7.33–7.25 (m, 3H,
Ar-H), 6.99 (d, 3J = 8.1 Hz, 2H, Ar-H), 6.91 (t, 3J = 7.2 Hz, 1H, Ar-
H), 3.39 (s, 8H, 4 CH2). 13C NMR (75.5 MHz, CDCl3): d
(ppm) = 150.8 (Cq), 149.0 (CHAr), 148.2 (CHAr), 132.3 (CH@N),
132.2 (CHAr), 132.0 (Cq), 129.2 (2CHAr), 123.5 (CHAr), 120.4
(CHAr), 116.6 (2CHAr), 50.8 (2CH2), 48.9 (2CH2). Mp: 111–113 C
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(2g)
According to GP-1: 50.0 mg (282 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 30.2 mg (26.5 lL, 282 lmol, 1.00 equiv) 4-
pyridinecarboxaldehyde, 1.0 mL toluene, stirring for 5 h. Yield:
75.0 mg (99%), orange solid. 1H NMR (300 MHz, CDCl3): d
(ppm) = 8.55 (d, 3J = 6.0 Hz, 2H, Ar-H), 7.46 (d, 3J = 6.0 Hz, 2H, Ar-
H), 7.43 (s, 1H, CH@N), 7.33–7.27 (m, 2H, Ar-H), 6.98 (d,
3J = 7.8 Hz, 2H, Ar-H), 6.92 (t, 3J =7.2 Hz, 1H, Ar-H), 3.41–3.40 (m,
8H, 4 CH2). 13C NMR (75.5 MHz, CDCl3): d (ppm) = 150.8 (Cq),
149.8 (2CHAr), 143.6 (Cq), 131.6 (CH@N), 129.2 (2CHAr), 120.5
(CHAr), 120.1 (2CHAr), 116.7 (2CHAr), 50.6 (2CH2), 48.9 (2CH2).
Mp: 156–158 C.
4.2.37. (E)-N-(Naphthalene-2-ylmethylen)-4-phenylpiperazin-
1-amine (2h)
According to GP-1: 40.0 mg (226 lmol, 2.00 equiv) 4-phenylpi-
perazin-1-amine, 35.3 mg (226 lmol, 1.00 equiv) 2-naph-
thaldehyde, 1.0 mL toluene, stirring overnight. Addition of 2.0 mg
(13.0 lmol, 0.06 equiv) 4-phenylpiperazin-1-amine after 18 h to
reach full conversion of the starting material after further stirring
for 6 h. Yield: 61.0 mg (82%), yellow solid. 1H NMR (300 MHz,
CDCl3): d (ppm) = 7.98–7.96 (m, 1H, Ar-H), 7.88 (s, 1H, CH@N),
7.84–7.80 (m, 4H, Ar-H), 7.48–7.46 (m, 2H, Ar-H), 7.34–7.29 (m,
2H, Ar-H), 7.02 (d, 3J = 8.1 Hz, 2H, Ar-H), 6.95–6.90 (m, 1H, Ar-H),
3.42 (s, 8H, 4CH2). 13C NMR (75.5 MHz, CDCl3): d (ppm) = 150.9
(Cq), 136.6 (CH@N), 133.8 (Cq), 133.5 (Cq), 133.4 (Cq), 129.2
(2CHAr), 128.3 (CHAr), 128.0 (CHAr), 127.8 (CHAr), 126.6 (CHAr),
126.2 (CHAr), 126.0 (CHAr), 123.1 (CHAr), 120.3 (CHAr), 116.6
(2CHAr), 51.2 (2CH2), 49.0 (2CH2). Mp: 195–198 C (dec.). HRMS
(EI+): m/z: calcd for C21H21N3 [M]+: 315.1736; found 315.1738.
4.2.38. (E)-4-Phenyl-N-(quinoline-2-ylmethylen)-piperazin-1-
amine (2i)
According to GP-1: 40.0 mg (226 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 35.5 mg (226 lmol, 1.00 equiv) 2-quinolinecar-
boxaldehyde, 1.0 mL toluene, stirring for 5.5 h. Yield: 59.0 mg
(83%), dark yellow solid. 1H NMR (300 MHz, CDCl3): d
(ppm) = 8.09 (s, 2H, Ar-H), 8.05 (d, 3J = 8.4 Hz, 1H, Ar-H), 7.86 (s,
1H, CH@N), 7.78 (dd, 3J = 8.1 Hz, 4J = 0.6 Hz, 1H, Ar-H), 7.72–7.67
(m, 1H, Ar-H), 7.52–7.47 (m, 1H, Ar-H), 7.33–7.28 (m, 2H, Ar-H),
7.00 (d, 3J = 7.8 Hz, 2H, Ar-H), 6.92 (t, 3J = 7.2 Hz, 1H, Ar-H), 3.52–
3.49 (m, 4H, 2CH2), 3.43–3.39 (m, 4H, 2CH2). 13C NMR (75.5 MHz,
CDCl3): d (ppm) = 155.6 (Cq), 150.8 (Cq), 147.7 (Cq), 136.1
(CH@N), 135.7 (Cq), 129.6 (CHAr), 129.2 (2CHAr), 128.7 (CHAr),
127.7 (CHAr), 127.6 (CHAr), 126.2 (CHAr), 120.4 (CHAr), 117.5
(CHAr), 116.7 (2CHAr), 50.7 (2CH2), 48.9 (2CH2). Mp: 210–212 C.
HRMS (EI+): m/z: calcd for C20H20N4 [M]+: 316.1688; found
316.1696.
4.2.39. (E)-N-(Naphthalene-1-methylen)-4-phenylpiperazin-1-
amine (2j)
According to GP-1: 50.9 mg (288 lmol, 1.00 equiv) 4-phenylpi-
perazin-1-amine, 44.9 mg (39.0 lL, 288 lmol, 1.00 equiv) 1-naph-
thaldehyde, 3.0 mL toluene, stirring for 4 h. Yield: 88.6 mg (98%),
brown solid. 1H NMR (300 MHz, CDCl3): d (ppm) = 8.60 (d,
3J = 8.1 Hz, 1H, Ar-H), 8.33 (s, 1H, CH@N), 7.91–7.87 (m, 2H, Ar-
H), 7.83 (d, 3 J = 8.1 Hz, 1H, Ar-H), 7.59–7.48 (m, 3H, Ar-H), 7.36–
7.30 (m, 2H, Ar-H), 7.03 (d, 3J = 7.8 Hz, 2H, Ar-H), 6.94 (t,
3J = 7.2 Hz, 1H, Ar-H), 3.47 (s, 8H, 4CH2). 13C NMR (75.5 MHz,
CDCl3): d (ppm) = 150.9 (Cq), 135.7 (CH@N), 133.9 (Cq), 131.5
(Cq), 130.7 (Cq), 129.2 (2CHAr), 128.8 (CHAr), 128.7 (CHAr),
126.3 (CHAr), 125.7 (CHAr), 125.5 (CHAr), 125.3 (CHAr), 123.8
(CHAr), 120.3 (CHAr), 116.6 (2CHAr), 51.3 (2CH2), 49.0 (2CH2).
Mp: 118 C.4.2.40. (E)-4-((4-(Pyridine-4-yl)piperazin-1-ylimino)methyl)-
benzene-1,3-diol (3a)
According to GP-1: 250 mg (1.40 mmol, 1.00 equiv) 4-(pyri-
dine-4-yl)piperazine-1-amine), 4.0 mL toluene, 190 mg
(1.40 mmol, 1.00 equiv) 2,4-dihydroxybenzaldehyde. Stirring at
100 C for 2 h. Trituration with 15 mL hot toluene yielded the pure
product. Yield: 310.0 mg (74%), brown solid. Rf (MeOH): 0.30. 1H
NMR (300 MHz, DMSO-d6): d (ppm) = 11.52 (br s, 1H, OH), 9.90
(br s, 1H, OH), 8.19 (br s, 2H, Ar-H), 7.97 (s, 1H, CH@N), 7.17 (d,
3J = 8.4 Hz, 1H, Ar-H), 6.88 (d, 3J = 6.0 Hz, 2H, Ar-H), 6.31 (dd,
3J = 8.4 Hz, 4J = 2.1 Hz, 1H, Ar-H), 6.24 (d, 4J = 2.1 Hz, 1H, Ar-H),
3.53–3.49 (m, 4H, 2CH2), 3.15–3.12 (m, 4H, 2CH2). 13C NMR
(75.5 MHz, DMSO-d6): d (ppm) = 159.1 (Cq-OH), 158.6 (Cq-OH),
154.1 (Cq), 149.8 (2CHAr), 142.7 (CH@N), 130.8 (CHAr), 111.4
(Cq), 108.6 (2CHAr), 107.0 (CHAr), 102.4 (CHAr), 50.7 (2CH2),
44.6 (2CH2). Mp: 270–273 C (dec.). HRMS (EI+): m/z: calcd for
C16H18O2N4 [M]+: 298.1430; found 298.1447.
4.2.41. (E)-4-((4-(4-Fluorophenyl)piperazin-1-ylimino)methyl)-
benzene-1,3-diol (3b)
According to GP-1: 150 mg (768 lmol, 1.00 equiv) 4-(4-ﬂuo-
rophenyl)piperazine-1-amine, 2.0 mL toluene, 110 mg (768 lmol,
1.00 equiv) 2,4-dihydroxybenzaldehyde. Stirring at 100 C for 2 h.
Recrystallization from 7 mL toluene yielded the pure product.
Yield: 67.8 mg (25%), brown solid. Rf (MeOH): 0.64. 1H NMR
(300 MHz, DMSO-d6): d (ppm) = 11.59 (br s, 1H, OH), 9.72 (br s,
1H, OH), 7.95 (s, 1H, CH@N), 7.17 (d, 3J = 8.4 Hz, 1H, Ar-H), 7.10–
6.99 (m, 4H, Ar-H), 6.31 (dd, 3J = 8.4 Hz, 4J = 2.4 Hz, 1H, Ar-H),
6.25 (d, 4J = 2.4 Hz, 1H, Ar-H), 3.26–3.25 (m, 4H, 2CH2), 3.18–3.16
(m, 4H, 2CH2). 13C NMR (75.5 MHz, DMSO-d6): d (ppm) = 159.0
(Cq-OH), 158.6 (Cq-OH), 157.7, 154.6 (1JC–F = 236.0 Hz, Cq-F),
147.4, 147.3 (4JC–F = 2.0 Hz, Cq), 142.3 (CH@N), 130.7 (CHAr),
117.7, 117.6 (3JC–F = 7.6 Hz, 2CHAr), 115.4, 115.1 (2JC–F = 21.9 Hz,
2CHAr), 111.4 (Cq), 107.0 (CHAr), 102.4 (CHAr), 51.1 (2CH2), 48.3
(2CH2). Mp: 176–178 C.
4.2.42. (E)-4-((4-m-Tolylpiperazin-1-ylimino)methyl)benzene-
1,3-diol (3c)
According to GP-1: 150 mg (731 lmol, 1.00 equiv) 4-m-
tolylpiperazine-1-amine, 2.0 mL toluene, 101 mg (731 lmol,
1.00 equiv) 2,4-dihydroxybenzaldehyde. Stirring at 100 C for 2 h.
Recrystallization from 2 mL toluene yielded the pure product.
Yield: 141.8 mg (58%), brown solid. Rf (MeOH): 0.65. 1H NMR
(300 MHz, DMSO- d6): d (ppm) = 11.60 (s, 1H, OH), 9.75 (br s, 1H,
OH), 7.95 (s, 1H, CH@N), 7.18–7.09 (m, 2H, Ar-H), 6.82–6.78 (m,
2H, Ar-H), 6.64 (d, 3J = 7.2 Hz, 1H, Ar-H), 6.31 (dd, 3J = 8.1,
4J = 2.1 Hz, 1H, Ar-H), 6.25 (d, 4J = 2.1 Hz, 1H, Ar-H), 3.31–3.28
(m, 4H, 2CH2), 3.17–3.15 (m, 4H, 2CH2), 2.26 (s, 3H, CH3). 13C
NMR (75.5 MHz, DMSO-d6): d (ppm) = 159.0 (Cq-OH), 158.6 (Cq-
OH), 150.5 (Cq), 142.3 (CH@N), 138.0 (Cq-CH3), 130.7 (CHAr),
128.7 (CHAr), 120.0 (CHAr), 116.4 (CHAr), 113.0 (CHAr), 111.4
(Cq), 107.0 (CHAr), 102.4 (CHAr), 51.1 (2CH2), 47.6 (2CH2), 21.3
(CH3). Mp: 135–139 C. HRMS (EI+): m/z: calcd for C18H21O2N3
[M]+: 311.1654; found 311.1634.
4.2.43. (E)-4-((4-Benzylpiperazin-1-ylimino)methyl)benzene-
1,3-diol (3d)
According to GP-1: 150 mg (785 lmol, 1.00 equiv) 4-ben-
zylpiperazin-1-amine, 2.0 mL toluene, 108 mg (785 lmol,
1.00 equiv) 2,4-dihydroxybenzaldehyde. Stirring at 100 C for 2 h.
Final puriﬁcation by recrystallization from 4.0 mL toluene yielded
the pure product. Yield: 134.0 mg (95%), beige solid. 1H NMR
(300 MHz, DMSO-d6): d (ppm) = 11.61 (br s, 1H, OH), 9.67 (br s,
1H, OH), 7.83 (s, 1H, CH), 7.33–7.25 (m, 5H, Ar-H), 7.12 (d,
3J = 8.4 Hz, 1H, Ar-H), 6.30 (dd, 3J = 8.4 Hz, 4J = 2.1 Hz, 1H, Ar-H),
6.23 (d, 4J = 2.1 Hz, 1H, Ar-H), 3.52 (s, 2H, CH2), 3.03 (s, 4H,
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(ppm) = 158.8 (Cq-OH), 158.5 (Cq-OH), 141.3 (CH@N), 137.9 (Cq),
130.6 (CHAr), 128.7 (2CHAr), 128.1 (2CHAr), 126.9 (CHAr), 111.5
(Cq), 106.9 (CHAr), 102.3 (CHAr), 61.6 (CH2), 51.4 (2CH2), 51.1
(2CH2). Mp: 225–228 C. HRMS (EI+): m/z: calcd for C18H21O2N3
[M]+: 311.1634; found 311.1656.
4.2.44. (E)-4-((4-Phenethylpiperazin-1-ylimino)methyl)benzene-
1,3-diol (3e)
According to GP-1: 100 mg (488 lmol, 1.00 equiv, 90% purity)
4-phenethylpiperazin-1-amine, 2.0 mL toluene, 60.7 mg
(439 lmol, 1.00 equiv) 2,4-dihydroxybenzaldehyde. Stirring at
100 C overnight. Final puriﬁcation by recrystallization from
20.0 mL toluene yielded the pure product. Yield: 148.5 mg (94%),
orange-brown solid. 1H NMR (300 MHz, DMSO- d6): d
(ppm) = 11.83 (br s, 1H, OH), 9.88 (br s, 1H, OH), 8.05 (s, 1H,
CH@N), 7.51–7.32 (m, 6H, Ar-H), 6.50 (dd, 3J = 8.4 Hz, 4J = 1.8 Hz,
1H, Ar-H), 6.43 (d, 4J = 1.8 Hz, 1H, Ar-H), 3.23 (br s, 2H, CH2),
2.98–2.93 (m, 2H, CH2), 2.83–2.70 (m, 8H, 4CH2). 13C NMR
(75.5 MHz, DMSO-d6): d (ppm) = 158.8 (Cq-OH), 158.5 (Cq-OH),
141.3 (CH@N), 140.2 (Cq), 130.6 (CHAr), 128.6 (2CHAr), 128.1
(2CHAr), 125.8 (CHAr), 111.5 (Cq), 106.9 (CHAr), 102.3 (CHAr),
59.2 (CH2), 51.6 (2CH2), 51.1 (2CH2), 32.8 (CH2). Mp: 211–214 C.
HRMS (EI+): m/z: calcd for C19H23O2N3 [M]+: 325.1790; found
325.1799.
4.2.45. (E)-4-((4-Cyclohexylpiperazin-1-ylimino)methyl)benzene-
1,3-diol (3f)
According to GP-1: 150 mg (818 lmol, 1.00 equiv) 4-cyclo-
hexylpiperazine-1-amine, 2.0 mL toluene, 113 mg (818 lmol,
1.00 equiv) 2,4-dihydroxybenzaldehyde. Stirring at 100 C for 2 h.
Trituration with 16 mL hot toluene yielded the pure product.
Yield: 110.0 mg (66%), brown solid. Rf (MeOH): 0.55. 1H NMR
(300 MHz, DMSO-d6): d (ppm) = 11.65 (s, 1H, OH), 9.69 (br s, 1H,
OH), 7.82 (s, 1H, CH@N), 7.11 (d, 3J = 8.4 Hz, 1H, Ar-H), 6.28 (dd,
3J = 8.4 Hz, 4J = 2.1 Hz, 1H, Ar-H), 6.21 (d, 4J = 2.1 Hz, 1H, Ar-H),
2.99 (br s, 4H, 2CH2), 2.65 (br s, 4H, 2CH2), 2.30–2.27 (m, 1H,
CH), 1.75–1.73 (m, 4H, 2CH2), 1.59–1.56 (m, 1H, CH), 1.19–1.05
(m, 5H, 2CH2, CH). 13C NMR (75.5 MHz, DMSO-d6): d
(ppm) = 158.8 (Cq-OH), 158.5 (Cq-OH), 141.1 (CH@N), 130.6
(CHAr), 111.5 (Cq), 106.9 (CHAr), 102.3 (CHAr), 62.2 (CH), 51.6
(2CH2), 47.4 (2CH2), 28.3 (2CH2), 25.8 (CH2), 25.2 (2CH2). Mp:
247–249 C (dec.). HRMS (EI+): m/z: calcd for C17H25O2N3 [M]+:
303.1947; found 303.1942.
4.2.46. (E)-4-((4-Cyclopentylpiperazin-1-ylimino)methyl)-
benzene-1,3-diol (3g)
According to GP-1: 150 mg (887 lmol, 1.00 equiv) 4-
cyclopentylpiperazine-1-amine, 2.0 mL toluene, 123 mg (887 lmol,
1.00 equiv) 2,4-dihydroxybenzaldehyde. Stirring at 100 C for 2 h.
Trituration with 16 mL hot toluene yielded the pure product. yield:
186.1 mg (76%), beige solid. Rf (MeOH): 0.57. 1H NMR (300 MHz,
DMSO-d6): d (ppm) = 11.63 (s, 1H, OH), 9.69 (br s, 1H, OH), 7.82 (s,
1H, CH@N), 7.12 (d, 3J = 8.4 Hz, 1H, Ar-H), 6.28 (dd, 3J = 8.4 Hz,
4J = 2.1 Hz, 1H, Ar-H), 6.22 (d, 4J = 2.1 Hz, 1H, Ar-H), 3.00 (br s, 4H,
2CH2), 2.58–2.49 (m, 4H, 2CH2), 2.46–2.44 (m, 1H, CH), 1.81–1.78
(m, 2H, CH2), 1.63–1.47 (m, 4H, 2CH2), 1.36–1.30 (m, 2H, CH2). 13C
NMR (75.5 MHz, DMSO-d6): d (ppm) = 158.8 (Cq-OH), 158.5 (Cq-
OH), 141.2 (CH@N), 130.6 (CHAr), 111.5 (Cq), 106.9 (CHAr), 102.3
(CHAr), 66.3 (CH), 51.2 (2CH2), 50.6 (2CH2), 29.9 (2CH2), 23.6
(2CH2). Mp: 237–239 C (dec.). HRMS (EI+): m/z: calcd for
C16H23O2N3 [M]+: 289.1790; found 289.1795.
4.2.47. (E)-4-((4-Phenylpiperidine-1-ylimino)methyl)benzene-
1,3-diol (3h)
According to GP-1: 50.0 mg (284 lmol, 1.00 equiv) 4-phenylpi-
peridine-1-amine (30), 1.0 mL toluene, 39.0 mg (284 lmol,1.00 equiv) 2,4-dihydroxybenzaldehyde. Stirring at 100 C for
2.5 h. Final puriﬁcation by recrystallization from 2.0 mL toluene
yielded the pure product. Yield: 48.0 mg (57%), yellow crystals.
1H NMR (300 MHz, CDCl3): d (ppm) = 11.77 (s, 1H, OH), 9.66 (br
s, 1H, OH), 7.89 (s, 1H, CH@N), 7.34–7.27 (m, 4H, Ar-H), 7.23–
7.20 (m, 1H, Ar-H), 7.14 (d, 3J = 8.4 Hz; 1H, Ar-H), 6.29 (dd,
3J = 8.4 Hz, 4J = 2.4 Hz, 1H, Ar-H), 6.23 (d, 4J = 2.4 Hz, 1H, Ar-H)
3.74–3.70 (m, 2H, CH2), 2.67–2.59 (m, 3H, CH, CH2), 1.88–1.80
(m, 4H, 2CH2). 13C NMR (75.5 MHz, CDCl3): d (ppm) = 158.7 (Cq-
OH), 158.5 (Cq-OH), 145.5 (Cq), 141.1 (CH@N), 130.6 (CHAr),
128.3 (2CHAr), 126.6 (2CHAr), 126.1 (CHAr), 111.7 (Cq), 106.8
(CHAr), 102.3 (CHAr), 51.6 (2CH2), 41.0 (CH), 31.7 (2CH2). Mp:
139–142 C. HRMS (EI+): m/z: calcd for C18H20O2N2 [M]+:
296.1525; found 296.1530.
4.2.48. (E)-4-((4-benzylpiperidine-1-ylimino)methyl)benzene-
1,3-diol (3i)
According to GP-1: 86.0 mg (453 lmol, 1.00 equiv, 96% purity)
4-benzylpiperidine-1-amine (34), 2.0 mL toluene, 60.1 mg
(435 lmol, 1.0 equiv) 2,4-dihydroxybenzaldehyde. Stirring at
100 C overnight. Yield: 134.0 mg (95%), yellow-brown solid. 1H
NMR (300 MHz, MeOD): d (ppm) = 7.82 (s, 1H, CH@N), 7.29–7.24
(m, 2H, Ar-H), 7.19–7.16 (m, 3H, Ar-H), 7.04 (d, 3J = 8.4 Hz, 1H,
Ar-H), 6.30 (dd, 3J = 8.4 Hz, 4 J = 2.4 Hz, 1H, Ar-H), 6.25 (d,
4J = 2.4 Hz, 1H, Ar-H), 3.61–3.57 (m, 2H, CH2), 2.58 (d, 3J = 6.9 Hz,
2H, CH2), 2.54–2.46 (m, 2H, CH2), 1.79–1.75 (m, 2H, CH2), 1.71–
1.63 (m, 1H, CH), 1.50–1.41 (m, 2H, CH2). 13C NMR (75.5 MHz,
MeOD): d (ppm) = 160.6 (Cq-OH), 160.5 (Cq-OH), 144.5 (CH@N),
141.6 (Cq), 132.3 (CHAr), 130.2 (2CHAr), 129.3 (2CHAr), 127.0
(CHAr), 113.4 (Cq), 108.1 (CHAr), 103.7 (CHAr), 53.3 (2CH2), 43.7
(CH2), 38.8 (CH), 32.1 (2CH2). Mp: 138–141 C. HRMS (EI+): m/z:
calcd for C19H22O2N2 [M]+: 310.1681; found 310.1683.
4.2.49. (E)-4-((4-Phenyl-1,4-diazepan-1-ylimino)methyl)-
benzene-1,3-diol (3j)
According to GP-1: 31.7 mg (166 lmol, 1.00 equiv) 4-phenyl-
1,4-diazepane-1-amine (40), 1.0 mL toluene, 21.9 mg (166 lmol,
1.00 equiv) 2,4-dihydroxybenzaldehyde. Stirring at 100 C over-
night. Yield: 50.0 mg (97%), brown-red oil. Rf (CH/EtOAc 3:1):
0.75. 1H NMR (300 MHz, DMSO-d6): d (ppm) = 11.39 (s, 1H, CH),
9.51 (br s, 1H, OH), 7.54 (s, 1H, OH), 7.18–7.12 (m, 2H, Ar-H),
7.06 (d, 3J = 8.4 Hz, 1 H, Ar-H), 6.75 (d, 3J = 8.4 Hz, 1 H, Ar-H),
6.58 (t, 3J = 7.2 Hz, 1H, Ar-H), 6.25 (dd, 3J = 8.4 Hz, 4J = 2.1 Hz, 1H,
Ar-H), 6.19 (d, 4J = 2.1 Hz, 1H, Ar-H), 3.63–3.62 (m, 2H, CH2),
3.52–3.50 (m, 2H, CH2), 3.43–3.37 (m, 4H, 2CH2), 1.99–1.95 (m,
2H, CH2). 13C NMR (75.5 MHz, DMSO-d6): d (ppm) = = 157.8 (Cq-
OH), 157.5 (Cq-OH), 147.1 (CH@N), 135.5 (Cq), 129.4 (CHAr),
129.2 (2CHAr), 115.5 (CHAr), 112.5 (Cq), 111.4 (2CHAr), 106.7
(CHAr), 102.3 (CHAr), 51.7 (CH2), 49.6 (CH2), 47.3 (CH2), 47.2
(CH2), 23.2 (CH2). HRMS (EI+): m/z: calcd for C18H21O2N3 [M]+:
311.1634; found 311.1616.
4.2.50. 4-((4-Phenylpiperazin-1-yl)methyl)benzene-1,2-diol (8)
A 25 mL Schlenk tube was ﬂushed with argon and charged with
250 mg (1.81 mmol, 1.00 equiv) 3,4-dihydroxybenzaldehyde,
7.0 mL anhydrous DCE and 294 mg (0.28 mL, 1.81 mmol,
1.00 equiv) 1-phenylpiperazine. To the orange solution were added
538 mg (2.54 mmol, 1.40 equiv) sodium triacetoxyborhydride and
100 lL (1.81 mmol, 1.00 equiv) acetic acid. The colorless suspen-
sion was stirred at rt overnight, during which the color of the sus-
pension turned bright yellow. The mixture was hydrolyzed by
addition of saturated NaHCO3 solution (10 mL) and concentrated
under reduced pressure. The residue was dissolved in EtOAc
(30 mL) and water (30 mL) and the layers were separated. The
aqueous layer was extracted with EtOAc (2  20 mL) and the com-
bined organic layers were washed with brine (25 mL), dried over
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tion by silica gel ﬁltration (DCM/MeOH 19:1, Rf = 0.38) yielded
the pure product. Yield: 135.9 mg (26%), brown solid. 1H NMR
(300 MHz, DMSO-d6): d (ppm) = 8.87 (br s, 2H, 2OH), 7.19 (t,
3J = 7.8 Hz, 2H, Ar-H), 6.90 (d, 3J = 8.1 Hz, 2H, Ar-H), 6.78–6.73
(m, 2H, Ar-H), 6.68–6.65 (m, 1H, Ar-H), 6.56–6.53 (m, 1H, Ar-H),
3.32 (s, 2H, CH2), 3.10 (br s, 4H, 2CH2), 2.47–2.46 (m, 4H, 2CH2).
13C NMR (75.5 MHz, DMSO-d6): d (ppm) = 150.9 (Cq), 144.9 (Cq-
OH), 144.1 (Cq-OH), 128.8 (2CHAr), 128.6 (Cq), 119.7 (CHAr),
118.6 (CHAr), 116.2 (CHAr), 115.2 (2CHAr), 115.0 (CHAr), 61.8
(CH2), 52.4 (2CH2), 48.1 (2CH2). Mp: 100–102 C. HRMS (EI+): m/
z: calcd for C17H20O2N2 [M]+: 284.1525; found 284.1540.
4.2.51. 3,4-Dimethoxy-N-(4-phenylpiperazin-1-yl)benzamide
(10)
A 25 mL Schlenk tube was charged with 100 mg (549 lmol,
1.00 equiv) 3,4-dimethoxybenzoic acid, 218 mg (140 lL,
1.83 mmol, 3.33 equiv) thionylchloride and one catalytic drop of
anhydrous DMF. The light yellow suspension was heated under
reﬂux for 3.5 h. The excess thionylchloride was removed under
high vacuum over a cooling trap to obtain a light yellow solid (acid
chloride). A 25 mL one-neck round bottom ﬂask was charged with
117 mg (659 lmol, 1.20 equiv) 4-phenylpiperazin-1-amine and
2.0 mL 10% aqueous NaOH (2.0 mL). The solution was cooled to
0 C and a solution of the acid chloride in 1 mL absolute DCM
was added. The mixture was stirred at rt for 30 min, during which
a colorless solid precipitated. The solid was collected by ﬁltration,
washed with DCM and dried under vacuum. Final puriﬁcation by
recrystallization from EtOH (25 mL) yielded the pure product.
Yield: 98.0 mg (53%), colorless solid. 1H NMR (300 MHz, CDCl3): d
(ppm) = 7.40 (br s, 1H, NH), 7.31–7.27 (m, 3H, Ar-H), 6.98–6.84
(m, 5H, Ar-H), 3.93–3.92 (m, 6H, 2OCH3), 3.40 (m, 4H, 2CH2),
3.12 (m, 4H, 2CH2). 13C NMR (75.5 MHz, CDCl3): d (ppm) = 165.2
(C@O), 151.9 (Cq-OCH3), 150.9 (Cq-OCH3), 149.1 (Cq), 129.2
(2CHAr), 126.2 (Cq), 120.3 (CHAr), 119.4 (CHAr), 116.5 (2CHAr),
110.8 (CHAr), 110.2 (CHAr), 56.0 (2CH2), 55.4 (2OCH3), 48.9 (2CH2).
4.2.52. N-(3,4-Dimethoxyphenyl)-4-phenylpiperazin-1-
carboxamide (12)
A 25 mL Schlenk tube was dried under vacuum, ﬁlled with
argon and charged with 500 mg (3.26 mmol, 1.00 equiv) 3,4-
dimethoxyaniline and 6.1 mL absolute EtOH. 1.07 g (4.90 mmol,
1.50 equiv) di-tert-butyl dicarbonate were added slowly and the
suspension was stirred at rt for 2.5 h. The mixture was transferred
to a one-neck round bottom ﬂask and concentrated under reduced
pressure. Drying under high vacuum overnight yielded the product
which was used in the next reaction without further puriﬁcation. A
15 mL Schlenk tube was dried under vacuum, ﬁlled with argon and
charged with 176 mg (166 lL, 1.09 mmol, 1.10 equiv) 1-
phenylpiperazine and 2.0 mL absolute THF. The yellow solution
was cooled to 0 C and 76.0 mg (474 lL, 1.18 mmol, 1.20 equiv)
n-butyllithium were added. The mixture was warmed to rt and a
solution of 250 mg (987 lmol, 1.00 equiv) of previously prepared
tert-butyl-3,4-dimethoxyphenylcarbamate in 2.0 mL absolute THF
was added dropwise. The greenbrown solution was heated under
reﬂux for 5 h. The mixture was hydrolyzed with 5 mL 5% aqueous
HCl (5 mL). The aqueous layer was extracted with DCM (3  5 mL)
and the combined organic layers were washed with 5 mL saturated
aqueous NaHCO3 (5 mL), water (5 mL) and brine (5 mL). The
organic layer was dried over Na2SO4 and concentrated under
reduced pressure. Final puriﬁcation by column chromatography
(CH/EtOAc, size: 18.5  2.5 cm, 30 g SiO2) yielded the pure product.
Yield: 81.0 mg (25%), yellow-orange solid. Rf (CH/EtOAc 1:1): 0.19.
1H NMR (300 MHz, DMSO-d6): d (ppm) = 8.44 (br, 1H, NH), 7.26–
7.17 (m, 3H, Ar-H), 7.00–6.97 (m, 3H, Ar-H), 6.84–6.79 (m, 2H,
Ar-H), 3.71 (s, 3H, OCH3), 3.70 (s, 3H, OCH3), 3.59–3.56 (m, 4H,2CH2), 3.17–3.13 (m, 4H, 2CH2). 13C NMR (75.5 MHz, DMSO-d6):
d (ppm) = 155.0 (C@O), 150.8 (Cq-OCH3), 148.3 (Cq-OCH3), 143.9
(Cq), 133.9 (Cq), 128.8 (2CHAr), 119.1 (CHAr), 115.7 (2CHAr),
112.0 (CHAr), 111.5 (CHAr), 105.3 (CHAr), 55.7 (OCH3), 55.2
(OCH3), 48.3 (2CH2), 43.5 (2CH2). Mp: 122 C–125 C.
4.2.53. 3,4-Diﬂuorophenyl-4-phenylpiperazin-1-carboxylate
(14)
A 15 mL Schlenk tube was dried under vacuum, ﬁlled with
argon and charged with 500 mg (3.84 mmol, 1.00 equiv) 3,4-di-
ﬂuorophenol, 2.0 mL absolute DCM and 624 mg (3.84 mmol,
1.00 equiv) 1,10-carbonyldiimidazole. The yellow mixture was stir-
red at rt for 1.5 h. To reach full conversion of the starting material
(GC–MS analysis) 605 mg (3.72 mmol, 0.97 equiv) 1,10-car-
bonyldiimidazol, dissolved in 1 mL DCM, were added and the mix-
ture was stirred at rt for further 20 h. The product solution was
used in the next reaction without work up or any puriﬁcation step.
623 mg (590 lL, 3.84 mmol, 1.00 equiv) 1-phenylpiperazine were
added to the product mixture of 3,4-diﬂuorophenyl-1H-imidazol-
1-carboxylate. After 1 h stirring at rt once more 25.0 mg (20 lL,
150 lmol, 0.04 equiv) 1-phenylpiperazine were added to reach full
conversion (GC–MS analysis). The mixture was stirred at rt for 2 h
and washed with water (2  5 mL). The organic layer was dried
over MgSO4 and concentrated under reduced pressure. As the
obtained solid was not pure enough, even after silica gel ﬁltration
(CH/EtOAc 5:1, Rf = 0.18), it was dissolved in DCM (5 mL) and
washed with 5 mL 2 M NaOH (5 mL). The organic layer was dried
over Na2SO4, concentrated under reduced pressure and dried under
high vacuum to yield the pure product. Yield: 246.0 mg (20%), light
yellow solid. Rf (DCM): 0.49. 1H NMR (300 MHz, CDCl3): d
(ppm) = 7.34–7.29 (m, 2H, Ar-H), 7.15 (q, 3J = 9.0 Hz, Ar-H), 7.07–
6.86 (m, 5H, Ar-H), 3.82–3.75 (m, 4H, 2CH2), 3.25 (t, 3J = 5.4 Hz,
4H, 2CH2). 13C NMR (75.5 MHz, CDCl3): d (ppm) = 153.0 (C@O),
151.7, 151.5, 148.4, 148.2 (1JC–F = 249.5 Hz, 2JC–F = 13.9 Hz, Cq-F),
149.7, 149.6, 146.5, 146.3 (1JC–F = 245.7 Hz, 2JC–F = 12.5 Hz, Cq-F),
147.0, 146.9, 146.8, (3JC–F = 8.8 Hz, 4JC–F = 3.2 Hz, Cq), 129.3
(2CHAr), 120.9 (CHAr), 117.7, 117.6, 117.5 (CHAr), 117.2 (Cq),
116.9 (2CHAr), 111.9, 111.6 (2JC–F = 19.9 Hz, CHAr), 49.6 (2CH2),
43.9 (2CH2). Mp: 94–96 C. HRMS (EI+): m/z: calcd for
C17H16O2N2F2 [M]+: 318.1180; found 318.1182.
4.3. Triglyceride hydrolase activity assay
For the determination of TG hydrolase activity cell lysates of
COS-7 cells overexpressing recombinant murine ATGL were used.
Therefore, monkey embryonic kidney cells (Cos-7; ATCC CRL-
1651) were cultivated in Dulbeccos modiﬁed eagles medium
(DMEM, GIBCO, Invitrogen Corp., Carlsbad, CA), containing 10%
fetal calf serum (FCS, Sigma–Aldrich) and antibiotics (100 IU/mL
penicillin and 100 lg/mL streptomycin) at standard conditions
(37 C, 5% CO2, 95% humidiﬁed atmosphere). Cells were transfected
with 1 lg DNA complexed to Metafectene (Biontex GmbH, Munich,
Germany) in serum free DMEM. After 4 h the mediumwas replaced
by DMEM supplemented with 10% FCS. For the preparation of cell
lysates, cells were washed with 1 phosphate buffered saline, col-
lected using a cell scraper, and disrupted in buffer A (0.25 M
sucrose, 1 mM EDTA, 1 mM dithiothreitol, 20 lg/mL leupeptine,
2 lg/mL antipain, 1 lg/mL pepstatin, pH 7.0) by sonication
(Virsonic 475, Virtis, Gardiner, NJ). Nuclei and unbroken cells were
removed by centrifugation (1000g, 4 C, for 10 min). Protein con-
centration of the cell lysates were determined by Bio-Rad protein
assay according to the manufacturer’s protocol (Bio-Rad 785, Bio-
Rad Laboratories, Munich, Germany), using BSA as standard.
The triolein (TO) substrate was prepared as described. 20 In
brief, 330 lM triolein (40,000 cpm/nmol) (GE Healthcare) was
emulsiﬁed with 45 lM phosphatidylcholine/phosphatidylinositol
2916 N. Mayer et al. / Bioorg. Med. Chem. 23 (2015) 2904–2916(3:1) (Sigma) in 100 mM potassium phosphate buffer (pH 7.0) by
sonication (Virsonic 475, Virtis) and was adjusted to 5% (w/v) fatty
acid free bovine serum albumin (BSA, Sigma). 100 lL (20 lg pro-
tein) cell lysate or 2 ll puriﬁed recombinant LPL (Sigma–Aldrich)
were incubated with 100 lL TO substrate in the presence or in
the absence of inhibitors in a water bath for 1 h at 37 C. After
incubation, the reaction was terminated by adding 3.25 mL of
methanol/chloroform/heptane (10:9:7) and 1 mL of 0.1 M potas-
sium carbonate, 0.1 M boric acid (pH 10.5). After centrifugation
(800 g, 15 min), the radioactivity in 1 mL of the upper phase was
determined by liquid scintillation counting.
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